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Poster Presentations from the 2018 Maine Medical Center 
Research Institute (MMCRI) Summer Student Research 
Program
The following posters were presented as part of the 2018 MMCRI Summer Student Research Program. 
This program offers undergraduates and medical students a unique opportunity to conduct research in 
diverse clinical and biomedical science fields during the summer months. During the paid ten-week program, 
students participate in mentored independent research projects either in our state-of-the-art research facility, 
or working with physicians in a hospital setting to impact patient care or the outcome of treatment. Students 
also attend lectures and workshops featuring topics including bioethics, animal use in biomedical science and 
scientific presentation skills, and have the opportunity to attend presentations by guest scientists and MMCRI 
faculty. All students give a final presentation, which in 2018 involved a three minute oral presentation called a 
“Three Minute Thesis” as well as a scientific poster presentation.   All authors have an affiliation with MMCRI, 
unless otherwise noted.
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1. Isolate mitochondria to run a SeaHorse assay to determine the dose of etomoxir that results in off 
target effects on the electron transport chain.
2. Determine the exact doses of etomoxir in combination with bortezomib and dexamethasone that are 
most effective in multiple myeloma cell lines.
3. Seed myeloma cells in direct, or indirect, co-culture with bone marrow adipocytes to investigate 
whether etomoxir has a greater negative effect on cell viability in a high lipid environment. 
4. Create a CPT1 knockdown model using lipofectamine and siRNA to see the effect of complete inhibition 
of fatty acid oxidation without the risk of off-target effects. 
5. Treat multiple myeloma cells with a combination of etomoxir and orlistat (fatty acid synthesis inhibitor) 
to try to reduce cell viability and to determine the role of lipids in myeloma cells. 
6. Create a drug combination therapy including etomoxir, orlistat, and anti-myeloma drugs. 
The Role of Lipid Metabolism in Multiple Myeloma
1. In Vitro Measurement of Cell Viability using Bioluminescent Imaging for MM Cells 
Treated with Etomoxir
MM1S bioluminescence 
read at 24 (A) and 72 (B) 
hours after various 
doses of etomoxir were 
added.  MM1S cells 
were seeded at a cell 
density of 40,000 
cells/well. OPM2 
bioluminescence read 
at 24 (C) and 72 (D) 
hours after various 
doses of etomoxir were 
added. MM1R 
bioluminescence read 
at 24 (E) and 72 (F) 
hours after various 
doses of etomoxir were 
added. 
*, p< 0.05; 
****, p< 0.0001 
FUTURE DIRECTIONS
Cell Culture: MM1S (gfp+/luc+), MM1R (gfp+/luc+), and OPM2 (mcherry/luc+) were seeded at various densities into 
clear and white 96 well plates.
Drug administration: Etomoxir (CPT1 inhibitor), Bortezomib (proteasome inhibitor), and Dexamethasone 
(corticosteroid that reduces inflammation) were added at various doses 24 hours after the cells were seeded. 
Bortezomib and dexamethasone are common pharmacological anti-myeloma treatments. 
Cell Number: Bioluminescent imaging (BLI) was used to quantify cell viability. Luciferin (10 µL) was added to each 
well and incubated for 15 minutes before reading with Glomax® Microplate Reader. BLI was read after 24, 48, 72, 
and 96 hours after the drugs were administered to the cells. 
1. We have seen a decrease in cell viability in our in vitro models with the MM1S, MM1R, and OPM2 
multiple myeloma cell lines when treated with etomoxir only.
2. Our preliminary data showing that etomoxir decreased cell viability, suggests that multiple myeloma 
may utilize fatty acid metabolism as a source of energy. 
3. Combination treatments of etomoxir with other anti-myeloma drugs, such as bortezomib and 
dexamethasone showed a significant decrease in cell viability when compared to the control in MM1S 
and MM1R cell lines.
4. While we are seeing a trend in a reduction of cell viability with the use of etomoxir in all cell lines, more 
research is required to confirm this data and refute any claims of off target effects.
•Multiple Myeloma (MM) is the second most common type of hematological cancer, formed from a series of 
oncogenetic mutations to the plasma cells of the bone marrow (1). 
•Initially patients respond well to chemotherapeutic treatment, but almost all eventually develop resistance to these 
treatments and experience relapse. 
•Myeloma thrives in the unique and complex  bone marrow microenvironment. Also, within the bone marrow are bone 
marrow adipocytes (BMA) that form bone marrow adipose tissue and account for 50-70% of the total bone marrow 
volume. It is believed that BMAT provides a source of energy that aids in multiple myeloma cell metastasis (2). 
•Fatty acid oxidation is the process by which cells convert long chain fatty acids into NADH, FADH2, and ATP in the 
mitochondria.  
•CPT1 is a transport enzyme in the outer mitochondrial membrane that transports long chain fatty acids into the inner 
mitochondrial space. It is the first, yet rate limiting enzyme of the carnitine system and subsequently of fatty acid 
oxidation (3).
•Etomoxir (Eto) is an pharmacological irreversible inhibitor of CPT1, effectively inhibiting fatty acid oxidation. 
•In other cancers, such as breast and prostate cancer, inhibiting fatty acid oxidation with the use of etomoxir has been 
proven to reduce cancer cell viability and proliferation. 
•Recently etomoxir has been shown to have off target effects by inhibiting complex one of the electron transport chain 
at high dosages (4).
INTRODUCTION
•In addition to a potential energy source, BMAT has been shown 
to increase MM’s resistance to chemotherapeutic treatments (5). 
•We are examining the effect of etomoxir on different MM cell 
lines and if it increases MM sensitivity to chemotherapeutic drugs. 
Objective and Aims: An in vitro investigation at the effects 
of inhibiting CPT1 on MM cells and to design a drug 
combination treatment that effectively reduces MM cell 
viability.
Hypothesis: Inhibiting fatty acid oxidation in multiple 
myeloma cell lines will reduce cell viability and increase 
their sensitivity to other chemotherapeutic drugs. 
Cell viability of (A) OPM2 and (B) MM1R cells treated with etomoxir (eto) at 0 µM, 5 µM or 12.5 µM, in addition to various 
doses of bortezomib (bort), specifically 0 nM,  0.25 nM, 1 nM, or 5 nM. Bioluminescence was used to measure tumor cell 
number and was read 72 hours after the drugs were administered. OPM2 cells were seeded at 20,000 cells/well in 96-
well plates. *, p<0.05; **, p<0.01.
2. In vitro Combination Treatment of Etomoxir and Bortezomib
3. In vitro Combination Treatment of Etomoxir and Dexamethasone Co-Cultured with 
MSCs 
MM1S cells were directly co-cultured with mouse 
mesenchymal stem cells (mMSCs) for 24 hours 
before etomoxir (5µM) and dexamethasone 
(0.5µM) were administered . The mMSCs were 
seeded at a cell density of 7500 cells/well. The 
MM1S cells were seeded at a cell density of 5000 
cells/well. Statistical analysis was done using one 
way ANOVA test. *, p<0.05; ****p< 0.0001.
A
B
OPM2: Etomoxir + Bortezomib
MM1R: Etomoxir + Bortezomib
Bioluminescence read 24 hours after 500 µM etomoxir was added to the 
cells. MM1S cultured at a cell density of 40,000 cells/well. 
****, p< 0.0001 
A B
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E F
MM1S 24 hour
OPM2 24 hour
MM1R 24 hour
MM1S 72 hour
OPM2 72 hour
MM1R 72 hour
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Figure 1 : Melone et al. Cell Death & Disease 2018. The carnitine system processes 
long-chain fatty acids across the mitochondrial membrane, forming acylcarnitine. 
Acylcarnitine then enters the mitochondrial matrix via carnitine-acylcarnitine
translocase (CACT) to undergo β-oxidation. Once in the form of Acetyl CoA, the 
fatty acid  enters the Krebs cycle to produce ATP. (6)
Eto 5µMEto 0 µM
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Loss of miR-199b promotes expansion of myeloid-committed
progenitors differentiated from bone marrow and spleen HSCs 
1Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine
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Background: Perturbed hematopoietic stem cell (HSC) homeostasis can cause blood cancers
including acute myeloid leukemia (AML). To avoid this, HSC proliferation, survival and
differentiation must be properly balanced. There is emerging evidence that microRNAs (miRNAs)
might be well suited to regulate these decisions. Indeed, reports suggests that dysregulation of
microRNA expression in HSCs can lead to AML development.
Rationale: We and others have reported a significant down-regulation of microRNA 199b (miR-
199b) in bone marrow from AML patients. Recently, mRNA expression analyses revealed that
miR-199b is markedly enriched in hematopoietic stem cells (HSC) compartment, suggesting that
miR-199b may regulate HSCs function. Our flow cytometry analyses of bone marrow cells
showed elevated frequencies of primitive HSCs and myeloid progenitors in mice harboring
genetic deletion of miR-199b.
Hypothesis: Loss of miR-199b affects proliferation of HSCs and myeloid progenitors, and favors
myeloid differentiation.
Aim: HSC behavior is regulated by its microenvironment, thus the goal of this study was to
assess whether the response of HSPCs lacking miR-199b to GM and GEMM depends on the
tissue microenvironment in which hematopoiesis occurs.
Experimental Approach:
In vitro; In this study, we used a colony-forming unit (CFU) assay as validated in vitro that can
detect an increase or decrease in the frequency of hematopoietic stem and progenitor cells
(HSPCs) proliferation and/or changes in differentiation potential in response to stimulatory agents,
such as GM and GEMM. Therefore, CFU on GM and GEMM media was assessed to determine
proliferation abilities of HSPC from miR-199b KO bone marrow and spleen after primary,
secondary, and tertiary plating as compared to WT.
In vivo; A bone marrow transplantation study was utilized to assess the ability of miR-199b KO
HSC cells to repopulate blood cells in healthy host mice exposed to sublethal irradiation.
Results: We found that miR-199b deletion decreases HSCs clonogenic potential, but
favors GM myeloid differentiation and propagation of myeloid-committed progenitors. CFU-GM
and CFU-GEMM were decreased in the splenic HSPCs from miR-199b KO mice as compared to
WT counterparts. These results showed that splenic hematopoiesis is altered in miR-199b KO
mice. CFU-GM assays revealed a similar behavior of miR-199b-null HSPC from both the bone
marrow and spleen niches; indicating that extracellular factors did not play a significant role in
such differences. Our transplantation study showed that miR-199b KO HSCs have a greater
ability to repopulate myeloid and lymphoid cells than WT HSCs.
Further exploration into the effect of miR-199b in HSC self-renewal and progenitor differentiation
will help us to understand the functional role of miR-199b in early hematopoiesis.
Figure 1. Experimental design for in vitro colony-
forming unit (CFU) assays. Bone marrow and spleens
were harvested from N=3 wild type (WT) and miR-199b
KO mice. Cells were plated in MethoCult GM 3534 media
for myeloid progenitor differentiation or MethoCult GEMM
3434 medium that promotes multi-lineage differentiation.
Cells were kept at 37ºC with 5% CO2 and replated at 12
day intervals. Manual counting of cells was done after
imaging on STEMvision scanner.
Figure 2. Experimental design for in vivo BMT
transplantation study. Bone marrow from N=3 WT and
KO mice carrying a CD45.2 marker was harvested and
transplanted to irradiated WT mice carrying a CD45.1
marker. At 4, 8 and 12 weeks, blood samples were
taken from both mice for flow cytometry to determine
donor percentage of mature myeloid and lymphoid cells
in peripheral blood.
Figure 4. miR-199b deletion decreases colony forming abilities of splenic HSPCs at first
plating. A) Representative images of colony forming assays for splenic HSPCs on GM
differentiation medium (CFU-GM) performed in WT and miR-199b KO mice (n=3) for 2.5 and 5.0 x
105 cells. B) Representative images of colony forming assays for granulocyte, monocyte, erythroid,
myeloid and megakaryocytes differentiation medium (CFU-GEMM) performed in spleen cells from
WT and miR-199b KO mice (n=3) for 2.5 and 5.0 x 105 cells. C) Total CFU-GM and CFU-GEMM for
spleen cells in WT and miR-199b KO mice.
Figure 7. miR-199b KO HSCs have a greater ability to repopulate myeloid cells in the
irradiated host mice than WT HSCs. Donor chimerism (%) was measured at 4, 8 and 12 weeks
post-transplantation of BM from WT and miR-199b KO mice into sublethally irradiated host mice.
Figure 6. miR-199b KO mice show increased splenic myeloid progenitor proliferation as
compared to WT mice. A) Representative images of serial colony-replating assays of secondary
plating for myeloid progenitors (CFU-GM) performed in spleen cells from WT and miR-199b KO mice
(n=3) for 2.0 x 104 cells. B) Representative images of serial colony-replating assays of second
plating for granulocyte, erythroid, myeloid and megakaryocytes progenitors (CFU-GEMM) performed
in first plated spleen cells from WT and miR-199b knockout mice (n=3) for 2.0 x 104 cells. C)
Subsequent CFU replating assays for myeloid progenitors in CFU-GM media for 2.0 x 104 cells. D)
Subsequent CFU replating assays for multi-lineage progenitors in CFU-GEMM media for 2.0 x 104
cells.
Figure 3. miR-199b KO HSPCs from bone marrow (BM) have
decreased colony forming abilities on GM medium at first plating.
A) Representative images of colony forming assays for HSPCs
differentiating into myeloid lineages (CFU-GM) performed in BM cells
from WT and miR-199b KO mice (n=3) for 2.0 x 103 lineageneg c-kitpos
cells. B) Representative images of colony forming assays of miR-199b
null HSPCs on CFU-GEMM, directing cells to multilineage differentiation
(CFU-GEMM). Assays were performed in BM cells from WT and miR-
199b KO mice (n=3) for 2.0 x 103 lineageneg c-kitpos cells. C) Total CFU-
GM and CFU-GEMM for BM cells in WT and miR-199b KO mice.
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Figure 5. miR-199b KO mice show increased proliferation of myeloid-committed progenitors. 
A) Representative images of serial colony-replating assays at secondary and tertiary plating for 
myeloid-committed cells (CFU-GM) derived from WT and miR-199b KO progeny cells at first plating. 
Assays were performed for 2.0 x 104 cells from the first plating. B) Representative images of serial 
colony-replating assays at secondary and tertiary plating for granulocyte, erythroid, myeloid and 
megakaryocytes progenitors (CFU-GEMM) derived from WT and miR-199b KO mice (n=3) at first 
plating.  Assays were performed for 2.0 x 104 cells. C) Subsequent CFU plating assays for myeloid 
progenitors in CFU-GM media for 1.0 x 104 and 2.0 x 104 cells. D) Subsequent CFU plating assays 
for multilineage progenitors in CFU-GEMM media for 2.0 x 104 cells. 
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In conclusion, our results indicate that attenuation of miR-199b activity
promotes myeloid progenitor proliferation. We found that miR-199b deletion
favors myeloid lineage commitment and expansion of myeloid progenitors
when HSPCs were isolated either from BM or spleen, suggesting that these
HSPCs features result from intrinsic changes rather then niche alterations.
Reduced colony forming abilities of splenic HSPC in miR-199b KO mice
suggest regulatory effects of miR-199b on splenic hematopoiesis. Future
studies will be focused to understand the mechanism of miR-199b regulation
of myeloid progenitor lineage commitment.
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• Developing a ccRCC model requires isolation of  ccRCC cells; cells were isolated from 
tumors, grown in culture, and depleted of  fibroblasts. 
• Three possibilities exist regarding how ECM changes,; new ECM deposited by tumors, ECM 
is degraded, or ECM is remodeled and exists in an alternate form. We used mass 
spectrometry and immunohistochemistry to explore these options.
• 786-Os, a ccRCC cell line, were grown on normal and denatured collagen IV to study which 
environment is more favorable for cancer growth. Secretion of  collagen was also studied.
• Remodeling of  ECM by damage or proteases can release previously hidden collagen epitopes 
that affect angiogenesis. In this study we targeted XL313, a collagen epitope linked to 
increased angiogenesis and inflammation in other cancer types and shown to be secreted by 
macrophages1. 
Abstract
Modeling Clear Cell Renal Cell Carcinoma: Characterization of the Tumor 
Extracellular Matrix
Anna Deck, Kyle Bond, Peter Brooks, Leif Oxburgh
Maine Medical Center Research Institute
Introduction
Methods
Results
Acknowledgements
Conclusions
• Method used to isolate cells from ccRCC tumors efficiently purifies cancer cells based on 
marker analysis. These cells would be appropriate for downstream disease modeling 
studies.
• Drastic changes in ECM composition and structure exists between normal and tumor 
ccRCC tissue. The relative abundance of  collagens varies significantly between the two 
groups.
• 786-Os preferentially adhere to denatured collagen IV, which leads to increased 
downstream α5 integrin signaling. 
• Secretion of  denatured collagen XL313 by 786-Os suggests a novel role of  XL313 in 
ECM remodeling in ccRCC. 
• XL313 collagen epitopes are highly expressed in tumors Tp18-S108 and Tp18-S109, but 
not in Tp18-S114, indicating both intratumor and patient heterogeneity. 
This project was funded by the National Institute of  Health. Thank you to Friesel lab for lending multiple reagents used in the 
immunofluorescence portion of  this project. Thank you to Dr. Sims-Lucas at the University of  Pittsburgh for providing ccRCC tumor and 
matching normal tissues.
1. Ames, J. J., Contois, L., Caron, J. M., Tweedie, E., Yang, X., Friesel, R., … Brooks, P. C. (2016). Identification of  an Endogenously Generated 
Cryptic Collagen Epitope (XL313) That May Selectively Regulate Angiogenesis by an Integrin Yes-associated Protein (YAP) Mechano-transduction 
Pathway. The Journal of  Biological Chemistry, 291(6), 2731–2750. http://doi.org/10.1074/jbc.M115.669614
2. Hsieh, J. J. et al. Renal cell carcinoma. Nat. Rev. Dis. Primers
3, 17009 (2017).
3. Nabi, S., Kessler, E. R., Bernard, B., Flaig, T. W., & Lam, E. T. (2018). Renal cell carcinoma: a review of  biology and pathophysiology. 
F1000Research, 7, 307. http://doi.org/10.12688/f1000research.13179.1 
Figure 4:  A) H&E sections of  ccRCC, 20x. B) Trichrome staining, 20x. C) Immunofluorescence of  paraffin sections for XL313 collagen 
epitope, 20x. Insert, 40x. Images were taken of  matching regions for each tumor, scale bars 200 µm and 50 µm in 40x.
Results
Figure 4. 
C
Hidden epitopes in collagen of  extracellular matrix
Mechanical damage or protease-
mediated exposure of   cryptic 
epitopes
Adapted with permission from Dr. Brooks
Collagen types-I, II, III
XL313
C-ter.N-Ter
RGDKGE
Epitope Amino Acid Sequence Cell Surface Receptors
avb3
Effects of  remodeling on cryptic epitopes Representation of  distinct cryptic regulatory 
elements identified in the ECM protein collagen
Figure 2. 
• Mass spectrometry: Tumor and normal tissues depleted of  cells run through data 
independent acquisition LCMS mass spectrometry to characterize proteins of  the ECM, 
and analyzed via SWATH. 
• Differential adhesion: 786-Os were seeded onto collagen IV and denatured collagen IV. 
Optical density was used to measure mean cell adhesion and western blots of  
downstream collagen signaling molecules were run. 786-O conditioned media was 
collected and analyzed via western blot for secretion of  collagen epitopes. 
• Immunohistochemistry: Paraffin embedded sections were stained with anti-XL313 and 
Collagen I, III, and IV cocktail following previously developed ECM staining procedure. 
H&E and Trichrome staining performed by MMCRI Histology Core. 
Renal cell carcinoma (RCC) is the most common kidney cancer, affecting nearly 64,000 
new patients every year2,3. Clear cell renal cell carcinoma (ccRCC) is the most common form of  
RCC, yet few treatment options exist for patients with this disease2.  Due to tumor heterogeneity 
and patient differences, developing personalized treatments is a high priority for treating afflicted 
patients. A major challenge in developing patient specific models is the complexity of  the tumor 
microenvironment (TME). One important component  of  the TME is the extracellular matrix 
(ECM), which has not been well characterized in ccRCC. Here we sought to understand the  
composition and structure of  ECM in individual patients. Tumor and matching normal ECM 
and cells were isolated from patient biopsies and characterized through LCMS mass 
spectrometry and immunofluorescence. Independent data acquisition and analysis using SWATH 
identified drastic changes in collagen content between tumor and normal cells. It was further 
determined that a denatured collagen environment increased cell adhesion and Akt signaling 
using an in vitro cell adhesion assay with the 786-O ccRCC cell line. XL313, a truncated  
RGDKGE collagen epitope, was shown to be secreted by 786-O cells. Immunohistochemical
staining of  patient tumors showed aberrant expression of  XL313 throughout  specific ccRCC 
tumors. These findings suggest that we have designed a cell isolation method that is viable to be 
used to create a ccRCC model to study cancer-ECM interactions. Additionally, the findings show 
a potential role of  denatured collagen in ccRCC growth. 
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Figure 1: A) Summary of  specific ccRCC patient diagnostics regarding used for current study. B) Validation staining of  ccRCC cell isolation. 
After culture for three passages, cells were collected using cytospin and stained for ccRCC markers(CK18 and Vimentin) and fibroblast markers 
(Vimentin and PDGFRβ) and costained with DAPI. 
Figure 3.
Tumor Grade Stage Gender Race Age
Tp18-S108 2 pT1a F White 60-69
Tp18-S109 2 pT3a M White 60-69
Tp18-S114 3 pT3a M White 80-89
• Cell isolation and characterization plan:
Figure 2: A) PCA analysis of  tumor and normal mass spectrometry data after mass spectrometry acquisition. Noted distinct clustering of  
tumor and normal cells. B) Differences in core ECM proteins between tumor and normal generated based on p-values <=0.05 from 
SWATH analysis. Overlapping collagen proteins were identified based on peak abundance analysis of  the non-significant pool. 
A B
Figure 3:  A) 786-O cells were seeded on natural and denatured collagen IV. Cell adhesion was measured using optical density. B) Western 
Blot of  downstream signaling molecules involved in αV integrin signaling pathway following seeding onto natural or denatured collagen 
IV. C) Western blot of  786-O conditioned media 786-Os after 72 and 48 hours identified XL313 (~15kb). Raw, a macrophage cell line, 
was used as an XL313 positive control. 
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• Differential adhesion onto denatured collagen repeated with isolated primary ccRCC cells.
• Confirm that XL313 is secreted by primary ccRCC cells, as well as other ccRCC cell lines.
• Staining for αv alongside other TME component cells should be performed to validate 
ability for cells to interact with XL313 epitope. 
• Treatment of  cell lines with anti-XL313 and measuring effect using a collagen invasion 
assay. 
• Xenograft 786-O cells into immune compromised mice and treatment with XL313 
antibody to understand the role of  XL313 on tumor growth in vivo
Future Directions
40x 40x 40x
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Incidence and Characteristics of Opioid-Related Cardiac Arrests at Maine Medical Center
Bailey West1,2, Teresa May3, John Dziodzio3, Tyler Nussinow1,  Barbara McCrum3, Christine Lord3, Ashley Eldridge3, Deanna Williams1, Lee Lucas4, Philip Stone3, Richard R. Riker3, David B. Seder3
1Maine Medical Center Research Institute, Scarborough, ME,  2Honors College, The University of Maine, Orono, ME,
3Department of Critical Care Services, Maine Medical Center, Portland, ME, 4Center for Outcomes Research, Portland, ME
• The opioid epidemic is a growing public-health concern, particularly in Maine [1], and misuse of opioids can lead to 
cardiopulmonary arrest [2]. In this study, we evaluated the incidence of opioid-related cardiac arrest (ORCA) admitted to Maine 
Medical Center (MMC) during 5 years between January 2013 and December 2017, and the differences in baseline characteristics, 
hospital course, and outcomes between ORCA and non-opioid-related cardiac arrest (non-ORCA) patients. 
• A retrospective review was performed on medical records of MMC cardiac arrest patients and in prospectively collected registry
data. An arrest was classified as an ORCA if it had no alternative explanation and met at least one of the following criteria: 1) EMS 
suspected the arrest was opioid-related, 2) the physician team suspected the arrest was opioid-related, or 3) an opioid-positive
toxicology screen [3].  Statistical methods used include the Wilcoxon rank-sum test and Fisher’s exact test.  A P-value less than or 
equal to 0.05 was considered significant. 
• Of 497 patients 51 (10.3%) had ORCA. ORCAs at MMC had increased from 15 in 2013-14 to 26 in 2016-17, a 73% increase. 
ORCA patients were significantly younger and healthier than other cardiac arrest patients but were more likely to have withdrawal
of life support due to severe brain injury. There was no significant difference in functional outcome and in-hospital mortality.
• Admissions to MMC for opioid-related cardiac arrest rose dramatically over 5 years. The demographics and clinical characteristics
of opioid-related cardiac arrest differ from other forms of cardiac arrest, while outcomes were similar.  More research into the
pathophysiology of ORCA is needed to better treat this population.
1. Russell, E. (2018, February 23). Drug overdoses killed a record 418 people in Maine last year. Retrieved from https://www.pressherald.com/2018/02/22/drug-
overdoses-killed-418-people-in-maine-last-year-up-11-percent/
2. Sakhuja, A., Sztajnkrycer, M., Vallabhajosyula, S., Cheungpasitporn, W., Patch, R., & Jentzer, J. (2017). National trends and outcomes of cardiac arrest in opioid 
overdose. Resuscitation, 121, 84-89.
3. Elmer, J., Lynch, M. J., Kristan, J., Morgan, P., Gerstel, S. J., Callaway, C. W., & Rittenberger, J. C. (2015). Recreational drug overdose-related cardiac arrests: Break 
on through to the other side. Resuscitation, 89, 177-181. doi:10.1016/j.resuscitation.2015.01.028
This research was supported by the Dana and Hilda Ray Willard Endowed Fund for Research Education and  the Maine 
Medical Center Research Institute Summer Student Research Program. 
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Figure 10. Venn diagram representing the similarities and 
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Table 1. Demographics and clinical features of non-
ORCA and ORCA patients.
Demographics
Non-ORCA (n =
446)
ORCA (n =
51) P value
Age (years) [mean±SD] 59.4 ± 15.8 40.7 ± 14.5 <0.0001
Female 142 (32%) 14 (27%) 0.6
Pre-arrest diseases
Previously healthy 55 (12%) 13 (25%) 0.016
Arrhythmia 84 (19%) 2 (4%) 0.005
Heart failure 77 (17%) 2 (4%) 0.014
Myocardial infarction 60 (13%) 3 (6%) 0.18
CCI [median (IQR)] 3 (1, 5) 0 (0, 1) <0.0001
Comorbid conditions 2 (1, 3) 0 (0,1) <0.0001
CPC 1 prior to arrest 397 (90%) 49 (98%) 0.07
Clinical features
Out-of-hospital arrest 327 (74%) 47 (94%) 0.0008
Witnessed 346 (79%) 27 (55%) 0.0006
Initial rhythm VT/VF 220 (52%) 7 (15%) <0.0001
Bystander CPR 81 (29%) 8 (20%) 0.26
Poor GCS motor subscore 313 (73%) 37 (77%) 0.6
Total ischemic time (min) 
[median (IQR)] 17 (10.3, 27) 16 (10, 25) 0.9
No-flow interval (min) 
[median (IQR)] 4 (1, 7) 5 (1.5, 8.5) 0.16
Shock on admission 285 (64%) 30 (59%) 0.5
Unless otherwise reported, data are presented as number and 
percentage.
Abbreviations: CCI - Charlson Comorbidity Index; CPC - Cerebral 
Performance Category; VT/VF - ventricular tachycardia/ventricular 
fibrillation; CPR - cardiopulmonary resuscitation; GCS - Glasgow Coma 
Scale
Figure 2. Method for classifying cardiac arrests as ORCA or non-ORCA.
An arrest was considered ORCA if it met at least one of the following criteria 
with no alternative explanation: 1) EMS suspects ORCA, 2) Physician team 
suspects ORCA, 3) Opiate-positive toxicology screen.  Based on reference 3.
Figure 1. Venn diagram representing the unknown 
similarities and differences between ORCAs and non-
ORCAs.
Figure 3. The International Cardiac 
Arrest Registry (INTCAR).
Figure 6. Comparison  of pre-arrest health between non-
ORCA and ORCA patients.
Opioid-related cardiac arrest (ORCA)
• Compare patterns of brain injury by serology and MRI between ORCA and non-ORCA patients
• Characterize ORCAs geographically throughout Maine
• A retrospective chart review was 
performed for patients admitted to MMC 
for cardiac arrest from January 2013 to 
July 2018.
• Each arrest was classified as ORCA or 
non-ORCA using a system based on the 
criteria described in [3].
• Demographic, hospital course, and 
outcomes data collected from the 
International Cardiac Arrest Registry 
(INTCAR).
• These characteristics were compared 
between ORCA and non-ORCA patients.
• Statistical analyses used include Fisher’s 
exact test and the Wilcoxon signed-rank 
test.
• A P value less than or equal to 0.05 was 
considered significant.
• The incidence of ORCAs at MMC has increased by 
73% from 2013 to 2017.
• ORCA patients were younger with fewer comorbid 
conditions.
• ORCA patients were less likely to have VT/VF.
• ORCA patients were likely to have more severe 
brain injuries.
• ORCA patients were less likely to undergo 
additional cardiac interventions.
• There was no difference in ischemic time or 
Glasgow Coma Scale motor subscore on 
presentation.
• There was no difference in the rate of in-hospital 
mortality and good functional outcome between 
ORCA and non-ORCA patients.
Figure 4. Incidence of ORCA at MMC 2013-2017.
Figure 5. Rate of ORCA and non-ORCA between January 2013 and 
July 2018.
Table 2. Hospital course for non-ORCA and ORCA 
patients.
Treatments/Tests
Non-ORCA (n =
466) ORCA (n = 51) P value
TTM administered 440 (99%) 50 (98%) 0.42
Target temperature (◦C)
33 63 (14%) 4 (8%) 0.28
34 4 (1%) 0 1 (NS)
35 29 (7%) 1 (2%) 0.35
36 24 (5%) 2 (4%) 1 (NS)
Coronary angiography 161 (37%) 5 (10%) 9.99E-05
PCI 74 (17%) 2 (4%) 0.013
Vasopressors / inotropes 
used during ICU stay 409 (93%) 44 (88%) 0.155
Mechanical circulatory 
support 424 (97%) 48 (94%) 0.2
Echo (within 12 h ROSC)
Normal >50% 104 (23%) 10 (20%) 0.6
Moderately impaired 30-
49% 90 (20%) 2 (4%) 0.0022
Severely impaired <30% 83 (19%) 5 (10%) 0.173
Echo not done 162 (36%) 33 (65%) 0.000124
MRI 21 (42%) 93 (21%) 0.0022
If MRI, when (days post-
ROSC) [median (IQR)] 4 (3, 5) 4 (3, 5) 0.9
Complications
Pneumonia 153 (34%) 26 (51%) 0.021
Seizures - clinical
None 362 (82%) 33 (66%) 0.0134
Yes partial 11 (2%) 1 (2%) 1
Yes generalized 50 (11%) 13 (26%) 0.0065
Yes subtle / non 
convulsive 5 (1%) 3 (6%) 0.038
Yes before temerature 
management 19 (4%) 4 (8%) 0.28
Yes during temperature 
management 40 (9%) 9 (18%) 0.075
Yes after temperature 
management 10 (2%) 4 (8%) 0.044
Myoclonus 248 (56%) 22 (44%) 0.13
Data are presented as number and percentage.
Abbreviations: TTM - targeted temperature management; PCI -
percutaneous coronary intervention;  ICU - intensive care unit; ROSC -
return of spontaneous circulation; MRI - magnetic resonance imaging
Table 3. Outcomes of non-ORCA and ORCA patients.
Outcome Non-ORCA (n =  466) ORCA (n = 51) P value
Hospital LOS (median [IQR]) 6 (3, 12) 8 (4, 13) 0.048
ICU LOS (median [IQR]) 4 (3, 7) 6 (4, 10) 0.0068
Condition at hospital discharge
Dead 251 (56%) 28 (55%) 0.155
GCS<8/noninteractive 5 (1%) 2 (4%) 0.7
Disorientated 16 (4%) 2 (4%) 0.7
Oriented 174 (39%) 18 (35%) 0.6
Agitated 2 (0.4%) 1 (2%) 0.28
Calm 39 (9%) 3 (6%) 1 (NS)
Nonambulatory 21 (5%) 2 (4%) 0.4
Ambulatory 148 (33%) 14 (27%) 0.9
CPC at hospital discharge
1 46 (10%) 3 (6%) 0.5
2 94 (21%) 11 (22%) 1 (NS)
3 41 (9%) 5 (10%) 0.8
4 5 (1%) 2 (4%) 0.155
5 255 (57%) 30 (59%) 0.9
CPC = good 140 (32%) 14 (27%) 0.6
Discharge diposition
Home 93 (21%) 11 (22%) 0.9
Inpatient rehabilitation 66 (15%) 7 (14%) 1 (NS)
Inpatient ventilator unit 2 (0.4%) 0 1 (NS)
Skilled nursing 20 (4%) 2 (4%) 1 (NS)
Hospice 2 (0.4%) 0 1 (NS)
Died after withdrawal of life support 220 (49%) 25 (49%) 1 (NS)
Died despite full support 30 (7%) 5 (10%) 0.39
Life support withdrawn 229 (53%) 26 (55%) 0.9
If yes, cause of WLST
Severe brain injury 169 (57%) 26 (81%) 0.0075
Patient intent not to be treated aggressively 69 (23%) 3 (9%) 0.11
Multi-organ failure 44 (15%) 19 (37%) 0.000542
Pre-existing advance directives 13 (4%) 1 (3%) 1
Unstable circulation 41 (14%) 19 (37%) 0.000169
Medical co-morbidity 39 (13%) 1 (3%) 0.15
If yes, day of WLST
Within 48 hours from admission 87 (20%) 5 (10%) 0.126
Day 3 - 4 60 (13%) 5 (10%) 0.66
Day 5 - 6 32 (7%) 3 (6%) 1 (NS)
After day 6 51 (11%) 14 (27%) 0.0034
Unless otherwise reported, data are presented as number and percentage.
Abbreviations: LOS - length of stay; ICU - intensive care unit; GCS - Glasgow Coma Scale; CPC - Cerebral Performance Category; 
WLST - withdrawal of life support
Figure 8. Hospital and ICU LOS for non-ORCA and ORCA 
patients.
Figure 9. Condition at hospital discharge for non-ORCA and 
ORCA patients.
• The rate of ORCAs increased at MMC and statewide from 2013 to 2018
• ORCA patients demographics and clinical features differ from other cardiac arrests
• ORCA patients have worse functional outcomes than non-ORCA cardiac arrest patients
• The pathophysiology of ORCA differs from other cardiac arrest populations
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Figure 7. Additional interventions for non-ORCA and ORCA 
patients.
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Spry1 deficiency in mice shows fat depot specific alterations in adipose tissue
responses to a high-fat Western Diet
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Bridget Mellon1, Shivangi Pande2, 3,Xuehui Yang3 and Robert Friesel2,3
The aim of this project was to investigate the effects of Spry1 deficiency on 
adipose tissue responses to a Western Diet. Spry1 is highly expressed in the 
adipocytes and adipocyte progenitors. We looked for a specific “coronal 
structures” around adipocytes that are indicators of fibrosis. We 
observed decreased coronal structures in the epididymal adipose tissue of Spry1 
-/- mice fed a WD compared to Spry1+/+ mice. Our results also demonstrated that 
Spry1 -/- mice have a higher incidence of KLF4 and F4/80 positive cell staining 
compared with Spry1+/+ mice, indicating that the difference in fibrosis may be 
due to differential expression of the above markers. Thus, loss of Spry1 may be 
protective against Western Diet induced adipose tissue dysfunction.
References
Yang, X., Gong, Y., He, Q., et al., (2017). Loss of Spry1 attenuates vascular 
smooth muscle proliferation by impairing mitogen-mediated changes in 
cell cycle regulatory circuits. Journal of Cellular Biochemistry, 119(4), 
3267-3279. doi:10.1002/jcb.26486
Wayne Orr, A., Hastings, N.E., Blackman, B.R., & Wamhoff, B.R. (2009). 
Complex Regulation and Function of the Inflammatory Smooth Muscle 
Cell Phenotype in Atherosclerosis. Journal of Vascular Research, 47(2), 
168-180. doi:10.1159/000250095
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Corrigendum: KLF4-dependent phenotypic modulation of smooth 
muscle cells has a key role in atherosclerotic plaque 
pathogenesis. Nature Medicine, 22(2), 217-217. doi:10.1038/nm0216-
217a
ABSTRACT 
INTRODUCTION
Atherosclerosis, an inflammatory disease characterized by arterial wall thickening 
and plaque accumulation, is a major cause of death worldwide.
MATERIALS and METHODS
RESULTS 
Figure 3 : Expression of KLF4 in eWAT and iWAT of HFD fed Spry1 -/- and Spry1+/+ 
mice
CONCLUSIONS
• We observed decreased crown-like structures in the adipose tissue of 
Spry1-/- mice fed a WD when compared to Spry1+/+ mice. This suggests 
that Spry1 deficiency may alter the response of adipose tissue to 
hypercholesterolemia and this response leads to a less fibrotic 
appearance.
• There appeared to be an increase (in both intensity and quantity) of F4/80 
and KLF4 positive cells in the adipose tissue of Spry1-/- mice compared 
to Spry1+/+. This suggests an increase in macrophage infiltration of 
Spry1-/- adipose tissue.
• Fibrosis is usually a result of macrophage accumulation (in this case, 
hypercholesterolemia- induced) and/or aging, and based upon our 
observed increase in F4/80 immunostaining we expected fibrosis to be 
higher in Spry1 -/- mice fed a WD. The unexpected presence of less 
fibrotic adipose tissue in the Spry1-/- mice (especially eWAT) suggests 
Spry1 deficiency disrupts the development of fibrosis under 
hypercholesterolemic conditions. Understanding the role of Spry1 in 
adipose tissue responses to a WD requires further study and may 
provide unique opportunities for the treatment obesity, diabetes and 
cardiovascular disease.
• It appears that Spry1 -/- mice, while they have increased atherosclerosis, 
also have more normal (healthier) looking adipose tissue when fed a 
Western Diet.
1 Biology Department, Gordon College, 255 Grapevine Rd. Wenham, MA 01984
2 Graduate School of Biomedical Sciences and Engineering, University of Maine
3 Maine Medical Center Research Institute, 81 Research Dr, Scarborough, ME 04074
Figure 4: Expression of F480 in eWAT and iWAT for HFD fed 
Spry1 -/- and Spry1+/+ mice
 
 
 
 
 
                                                          
                                                                   
 
 
 
 
 
                                
 
 
 
 
 
 
HFD feeding 
for 12 weeks 
Analysis of adipose tissue  
  Spry1 -/-  Spry1 +/+ • Mice were fed a 45% fat-kcal atherogenic diet.
• AAV-PCSK9-D377Y was injected into the mice 
in order to reduce LDL-receptor expression in 
the liver, inhibiting cholesterol absorption from 
the blood and creating a hypercholesterolemic 
state.
• Analysis of adipose tissue included 
immunohistochemistry with F4/80 and KLF4 
antibodies, which are markers of macrophages 
and stem cells respectively.
Figure 1: X-gal staining of Spry1-/- mice showing expression of Spry1 in the adipocyte cells 
in eWAT and iWAT tissue.
It presents itself as an inflammatory 
response, initiated by activation of the 
endothelial layer surrounding the vessel 
lumen. This activation then induces a 
phenotypic transition of the smooth muscle 
cells, from a dormant, contractile state, to a 
proliferative and migratory, synthetic state. 
Our lab has established that Spry1, a 
regulator of receptor tyrosine kinase (RTK) 
signaling, plays a critical role in the 
maintenance of the contractile VSMC 
phenotype by inhibiting their migration. Spry1 
is highly expressed in both the fibroblasts 
and smooth muscle cells in the vasculature of 
the heart, as well as in the adipocyte cells. 
x200 x200
x200
x200 x200
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Figure 2: H&E staining of eWAT showing less “crown-like” structures surrounding 
adipocytes of Spry1 -/- mice compared to Spry1+/+ mice.
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Spry1 -/-Spry1 +/+
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Spry1 -/-
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Resource Guide for CME in POCUS:
 Summary of expert guidelines for core applications 
and establishment of 3 tiers according to consensus 
opinion
 Needs assessment tool to determine training goals
 Compilation of previous assessment tools for each 
Tier 1 ultrasound application
Crafting a resource guide for curriculum building in EM POCUS Continuing Medical Education
Campbell Belisle Haley, Tufts University School of Medicine Maine Track Program
Ultrasonography (ultrasound) is a technology that uses high frequency sound waves to
generate moving images of tissue. Point of care ultrasound (POCUS) is ultrasound brought to
the patient and performed in real time. POCUS began in the 1990s as a tool used to improve
diagnosis, procedures, and screening in multiple specialties. POCUS has become particularly
important in emergency departments. This project explored the scope of POCUS training in
emergency medicine (EM), compared ways that competency in POCUS is assessed, and used
literature review to create an compilation of resources that aims to improve competency-
based POCUS education of Maine EM physicians.
Objectives
1. Review guidelines from experts and professional
organizations to determine core applications of EM POCUS
2. Identify pre-existing ultrasound assessment tools and review
associated validity evidence
3. Develop a needs-assessment survey to determine the current
use and training needs of ultrasound in Maine emergency
departments
3 Tiers of Core POCUS Applications were developed according to 
consensus expert opinion
Components of a high-quality CME Curriculum
“Writing a Curriculum”, University at Buffalo Office of Continuing Medical Education, http://medicine.buffalo.edu/cme/planning_cme/writing_a_curriculum.html
3. Detailed instructional methods: 
How will you teach them this material?
2 surveys and one structured interview were developed to assess 
the ultrasound training needs of Maine emergency physicians.
Adapted from Henwood et al, Annals of Emergency Medicine, 2014
1. Clear educational objectives: 
What will your participants 
learn?
2. Integrated feedback 
mechanisms: 
How will you determine what they 
learned?
Determine “core” ED 
applications of POCUS Review assessment tools 
available + their validity
Create a way to assess 
needs of physician 
population
26 published assessment tools were identified through 
literature review, 8 had evidence of validation studies
FAST Exam, RUQ Scan Emergent Cardiac Imaging: Parasternal 
Long Axis View
Scan for early intrauterine pregnancy
Evaluation of abdominal aorta
IJV Scan for Central Line Procedural 
Guidance
All scan images from: https://www.acep.org/sonoguide/
1) Objectives for a CME curriculum should be based on a) 
expert opinion of required applications for EM POCUS and 
b) assessment of training needs for a physician population
2) Many tools exist to assess skills in emergency POCUS, but 
few have been tested for validity
3) OSCE/SDOT checklists have the most validity evidence, but 
this assessment method requires presence of US experts
Conclusions
Results
Abstract + Background
Methods
• Manual search and MEDLINE search for ultrasound 
training recommendations
• MEDLINE search for previous ultrasound assessment 
tools
• Consultation with author of previous needs 
assessment tool to adapt for Maine
Sample SDOT Checklist for Ultrasound Competency Assessment
Patient-
centered 
needs
Provider-
centered 
needs
Geographic 
issuesExisting 
physical 
resources
Existing 
clinical 
resources
Political, 
administrative 
considerations
Needs 
assessment
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Time Course of  Cognitive Change after Severe Hypoglycemia
Charlotte	  Benoit1,	  Lori	  Brodsky2,	  MN,	  FNP,	  Irwin	  Brodsky2,	  MD,	  MPH
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  Research	  Institute,	  2Maine	  Medical	  Partners	  Endocrinology	  and	  Diabetes	  Center
Hypothesis
Summary & Conclusion
Abstract Methods
Introduction
Hypoglycemia,	  or	  episodes	  of	  low	  blood	  sugar,	  is	  
particularly	  prevalent	  in	  people	  with	  type	  1	  diabetes.	  This	  is	  
because	  taking	  too	  much	  exogenous	  insulin	  can	  lead	  to	  
extremely	  low	  blood	  sugar	  levels.	  This	  study	  focuses	  on	  the	  
cognitive	  effects	  of	  severe	  hypoglycemia,	  which	  requires	  the	  
aid	  of	  another	  person,	  and	  particularly	  Grade	  4HG,	  defined	  
as	  episodes	  of	  low	  blood	  sugar	  that	  result	  in	  seizure	  or	  
unconsciousness.	  It	  is	  well	  known	  that	  during	  and	  
immediately	  after	  a	  severe	  hypoglycemic	  episode,	  brain	  
functioning	  is	  slower	  and	  thinking	  can	  be	  ‘foggy’.	  This	  study	  
addresses	  the	  cognitive	  effects	  of	  severe	  hypoglycemia	  in	  
adolescents	  with	  type	  1	  diabetes	  over	  the	  span	  of	  a	  month,	  
instead	  of	  just	  in	  the	  immediate	  aftermath	  of	  an	  episode.	  
Participants	  ages	  12-­‐21	  take	  a	  computerized	  test	  to	  measure	  
memory,	  reaction	  time,	  and	  visual	  processing,	  in	  order	  to	  
assess	  their	  general	  cognitive	  functioning.	  Data	  from	  a	  pilot	  
study	  suggests	  that	  adolescents	  who	  experience	  an	  episode	  
of	  Grade	  4HG	  have	  impaired	  visual	  and	  verbal	  memory	  1-­‐2	  
weeks	  later.	  Data	  also	  suggests	  that	  visual	  and	  verbal	  
memory	  recover	  by	  one	  month	  after	  the	  episode.	  Based	  on	  
these	  preliminary	  findings,	  it	  seems	  that	  certain	  cognitive	  
abilities	  continue	  to	  be	  impaired	  even	  after	  hypoglycemic	  
symptoms	  are	  no	  longer	  noticeable.	  The	  study	  team	  
continues	  to	  conduct	  research	  and	  acquire	  data	  from	  
adolescents	  who	  have	  recently	  experienced	  severe	  
hypoglycemia,	  as	  well	  as	  control	  subjects.
The	  study	  team	  is	  testing	  adolescents	  ages	  12-­‐21	  who	  have	  
recently	  experienced	  an	  episode	  of	  Grade	  4HG,	  adolescents	  
who	  have	  type	  1	  diabetes	  but	  have	  not	  recently	  experienced	  
severe	  hypoglycemia,	  as	  well	  as	  adolescents	  without	  diabetes.	  
Each	  participants	  takes	  a	  25	  minute	  computerized	  test	  originally	  
meant	  to	  assess	  concussions	  called	  the	  ImPACT test.	  The	  testing	  
is	  conducted	  four	  times	  over	  the	  course	  of	  a	  month.
The	  study	  team	  hypothesized	  that	  adolescents	  ages	  12-­‐
21	  would	  experience	  a	  temporary	  impairment	  in	  their	  
visual	  and	  verbal	  memory	  1-­‐2	  weeks	  after	  experiencing	  
an	  episode	  of	  Grade	  4HG.
-­‐ Visual	  memory	  is	  impaired	  in	  adolescents	  with	  type	  1	  diabetes	  1-­‐
2	  weeks	  after	  experiencing	  an	  episode	  of	  severe	  hypoglycemia.	  
-­‐ Verbal	  memory	  is	  impaired	  in	  adolescents	  with	  type	  1	  diabetes	  1-­‐
2	  weeks	  after	  experiencing	  an	  episode	  of	  severe	  hypoglycemia.
-­‐ The	  memory	  impairments	  are	  temporary	  and	  cognitive	  
functioning	  normalizes	  by	  one	  month	  after	  an	  episode	  of	  severe	  
hypoglycemia.
A	  comparison	  of	  a	  non-­‐diabetic	  pancreas	  and	  a	  type	  1	  diabetic	  pancreas.	  Adapted	  from	  
Diabetes	  Daily;	  Causes	  of	  Type	  1	  Diabetes
Adapted	  from	  ImPACT Applications,	  Inc.,	  2018
Adapted	  from	  ImPACT Applications,	  Inc.,	  2018
Adapted	  from	  ImPACT Applications,	  Inc.,	  2018
Figure	  1.	  Symptom	  scores	  of	  
participants	  who	  had	  experienced	  an	  
episode	  of	  Grade	  4HG;	  2013.	  Used	  with	  
permission	  from	  Irwin	  Brodsky,	  MD.
Figure	  2.	  Scores	  of	  visual	  motor	  speed,	  verbal	  memory,	  and	  cognitive	  efficiency	  of	  
participants	  who	  had	  experienced	  an	  episode	  of	  Grade	  4HG;	  2013.	  Used	  with	  permission	  
from	  Irwin	  Brodsky,	  MD.
Figure	  3.	  Verbal	  memory	  scores	  of	  
participants	  who	  had	  experienced	  an	  
episode	  of	  Grade	  4HG,	  and	  control	  
subjects;	  2013.	  Used	  with	  permission	  
from	  Irwin	  Brodsky,	  MD.
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Needs Assessment and Quality Improvement of Pre-Transplant Patient Education
Elisabeth Lualdi, Dr. Paul Han, Jessica Begley, Dr. James Whiting
for the Maine Transplant Center
• Nationally, more than 115,000 patients are on 
the waiting list for a life-saving kidney 
transplant. 
• At the Maine Transplant Center (MTC), 100 
patients are on the waiting list, and about 50 
transplants are performed in a given year. 
• Patient Education at the MTC consists of a 
single educational class before evaluation. 
• Educational class creates scheduling demands 
that delay evaluation & treatment. 
• Many transplant candidates lack thorough 
understanding of treatment options.
• Knowledge deficits impede appropriate care 
following transplantation.
ConclusionsObjectives + MethodsIntroduction + Abstract Results
10 Weeks in a Nutshell
Prototype: A 5 Part Online Power Point with Audio.
Alternative Pathway for Education 
• Needs assessment revealed many problems 
and corrective measures to improve patient 
education.
• Nationally, there is a huge effort to improve 
patient education, given the prominence of 
kidney disease and the long wait for 
transplants. 
• Alternative Pathway for Education prototype 
will undergo future refinement but contains 
essential elements for improved education: 
limited length, prioritizing SSM and TTM 
models, chunking of information. 
• Hand-outs are in the process of a health-
literacy evaluation for better 
understandability. 
Skelton’s Recommendations for Educational Programs
• Limit the length. 
• Fit the format to the preferred way of learning. 
• Meet patients where they are in regard to treatment 
options and knowledge. 
• Explain complex issues in easy-to understand language. 
• Lessen the amount of information presented at one time 
(chunking).
A needs assessment  was conducted to explore 
ways to improve the educational system at MTC. 
Findings from a literature review and key 
informant interviews with MTC clinicians and 
patients revealed many gaps in MTC patient 
education. 
Using the SDM and TTM models as conceptual 
frameworks for redesigning the system, an 
alternative educational pathway to treatment was 
proposed.
The educational class has been reformatted into 
an online, modular based program offered to 
patients as an alternative. At the same time, 
educational handouts are being refined to 
enhance readability. 
• To improve the educational system for patients at 
the Maine Transplant  Center, aimed at facilitating 
informed and shared decision making.
• To conduct a needs assessment, based on literature 
review and key informant interviews, guiding efforts 
to redesign the educational intervention and identify 
areas for improvement.
• Staff Interviews 
• Presentation to 
Transplant Team 
• Self-education on health 
literacy
• CDC scanning of 
content delivered during 
class (power point and 
handouts)
• Patient Shadowing
• Class Attendance
• Literature Review
• Patient Phone 
Interviews: recent 
class attendees
MTC Clinician Interviews
• Patients should be given 
access to more resources for 
information. 
• Due to the volume of new 
referrals, patients have to wait 
a significant amount of time 
before they are booked for a 
class. 
• Patients are overwhelmed with 
information. 
• Patients have low health 
literacy.
Patient Interviews
• Only 45% of patients responded 
correctly to a fundamental piece of 
information: that you have to take 
anti-rejection medications for the 
life of your transplant. More than 
50% of patients reported being 
very unsatisfied with the progress 
of their treatment.
• Only 33% had completed some 
clearances (explained in the class) 
prior to Visit 1. 
• Using TTM, patients educated according to their specific readiness 
stage are 2 times more likely to engage in a recommended health 
behavior in the next 6 months than those with generalized 
recommendations.6
• Meta-analysis of 6 studies found that 40% of patients on dialysis 
lack health literacy in their ability to take care of themselves and 
change certain behaviors to support health.4
• An online program (educating patients on sun protection after a 
kidney transplant) had direct ties to Skelton’s Recommendations (see 
Methods section). Patients with initial low health literacy made 
significantly greater gains in knowledge than patients with adequate 
health literacy after completing the program.5
Literature Review
1. Elwyn, Glyn et al. A Three-Talk Model For Shared Decision Making: 
Multistage Consultation Process. 2017.
2. Swanson, Aaron. Trans Theoretical Model: Coaching and Cueing. 2015.
3. Skelton SL, et al. Applying best practices to designing patient education for 
patients with end-stage renal disease pursuing kidney transplant. 2015.
4. Lambert, Kelly et al. A Cross-Sectional Comparison of Health Literacy 
Deficits Among Patients With Chronic Kidney Disease, Journal of Health 
Communication. 2015.
5. Robinson JK et al.  Response Across the Health-Literacy Spectrum of 
Kidney Transplant Recipients to a Sun-Protection Education Program Delivered on 
Tablet Computers: Randomized Controlled Trial. 2015.
6. Waterman, AD et al. Educating Prospective Kidney Transplant Recipients 
and Living Donors about Living Donation: Practical and Theoretical Recommendations 
for Increasing Living Donation Rates. 2016.
Thank you to the entire Transplant Team, both at the 
hospital and at clinic. Thank you to my mentor, Dr. 
Whiting, as well as Dr. Han and Jessica Begley from 
LRC. I am very grateful for all the patients who allowed 
me to shadow and interview them. 
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A Comparison and Analysis of C2 Nerve Root Sacrifice Technique with Clinical Outcome
Emma C. England, Jeffrey E. Florman MD; Deborah A Cushing RN
Department of Neurosurgery, Maine Medical Center
The C2 nerve occupies a challenging anatomical 
position when inserting C1 lateral mass screws 
during atlantoaxial fixation and often requires root 
sacrifice or retraction. The method for C2 nerve 
sectioning is a potentially modifiable factor 
influencing clinical outcome and incidence of 
occipital neuralgia (ON). In this series, C2 nerve 
transection is performed routinely and clinical 
outcomes were assessed prospectively.
• Literature was reviewed in attempts to compare the described 
sacrifice techniques (Table 1).
• Inclusion of trauma patients requiring C1-2 fusion and C2 nerve 
root sacrifice between 2007 and 2017
• All of the patients charts were reviewed with attention ON 
incidence, narcotic use and numbness dictated in the to post-
operative office visits by the surgeon.
• The routine C2 sacrifice method was  described in detail by the 
surgeon.
• Telephone interviews were conducted using                                          
the American Chronic Pain Association (ACPA)                                
scale to assess quality of life, and the International          
Classification of Headache Disorder (ICHD-3)                              
scale to assess headaches and neck pain. 
Methods
66 C2 nerve roots were divided at the mid-portion of the C1 lateral 
mass using bipolar electrocautery. There were no instances of 
vertebral artery injury, transfusions, or CSF leakage. 
Abstract
Introduction
Methods
Table 1. Review of C2 Nerve Root Transection Techniques
Study & 
Year Cauterization
Sectioning 
Location ON (95% CI)
Aryan 
(2008)
bipolar 
electrocautery (EC) 
with metzenbaum
scissors
proximal to the 
DRG
1 of 102 
(p=0.010)
Squires and 
Molinari 
(2010)
monopolar EC mid-portion of C2 articulation
0 of 14 
(p=0.000)
Kang et al 
(2012)
bipolar EC with 
Malis scissors
mid-portion of 
C2 articulation
0  of 19 
(p=0.000)
Yeom et al 
(2013)
monopolar EC; 
bipolar EC & knife 
or metzenbaum
scissors
proximal to the 
DRG (or
through the 
DRG)
6 of 24 
(p=0.250)
Figure 1&2. Demonstrate the complex anatomy relevant to 
atlantoaxial fusion including the C2 nerve which is sacrificed 
in this cohort of patients.
Results
• C2 nerve root sacrifice is often used to minimize 
blood loss, operating time, risk of injury to the 
vertebral artery, and increase visibility. 
• Literature review reveals minimal  but variable 
description for cutting the nerve. 
• The C2 sacrifice technique in this series is most 
comparable to that described by Kang et al (2012). 
• 0 of 35 patients have symptoms consistent with ON 
at 3 month f/u with the surgeon
• 4 of 17 patients admitted to head/neck pain 
consistent with ON during delayed  phone f/u 
• 1 of the 4 patients was taking narcotics for head pain 
• It proves difficult to correlate sacrifice 
technique to occurrence of ON
Table 3. Breaks down the responses from the 17 patients with delayed f/u 
using the ACPA and ICHD-3 scales.
Table 1. An overview of literature describing C2 sectioning 
technique and location for patients who underwent sacrifice 
with follow up.
1. C2 nerve root sectioning technique is poorly 
understood
2. C2 nerve root sacrifice has excellent long term 
outcome
3. Transection technique may influence clinical 
outcome
Discussion
Acknowledgements
Learning Objectives
Thank you to all patients who elected to participate in the survey. 
Thank you to Dr. Florman for allowing me to use the data from his 
patients and for the knowledge to complete the study. Also, thank 
you to Debbie Cushing for her guidance.
Figure 3. Demonstrates the portion of the head effected by the C2 nerve.     
“A Variation of Type III Odontoid Fracture As Isolated Jaw Pain” By M Walid et. al.
vertebral artery
lateral mass Table 3. Results from delayed follow up patients
Severe Neck 
Pain ( ≥ 3)
Severe Headaches 
( ≥ 3) 
Occipital 
Pain QOL ≥ 6
# Effected 3 of 16 1 of 16 4 of 17 14 of 17 
Table 2. Results from early office visits and delayed follow up
# of 
Patients # Nerves Time Range 
Occipital 
Pain
Narcotics for 
head pain?
Type of 
Narcotic
Early f/u 
Office 
Visits
35 66 1-7 months (mean=2.7) 0 0 n/a
Delayed 
Phone 
Survey
17 31 0.5-4 years (mean=2.2) 4 of 17 1 of 17
liquid 
morphine
Table 2. Displays incidence of ON reviewed at the two f/u stages. 
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Characterization of a Novel Mouse Model with Adipocyte-specific Transgenic Expression of Mesoderm Specific Transcript
Gary R. Kersbergen, Rea Anunciado-Koza and Robert A. Koza
Introduction
Abstract
Mesoderm Specific Transcript (Mest) is expressed variably among genetically homogeneous mice and highly induced 
in adipocytes when mice are fed an obesogenic diet. The correlation of elevated Mest expression to increased body 
weight and fat mass gain implicate Mest as a potential epigenetic regulator of diet-induced obesity. In order to 
understand the regulation and function of Mest, a conditional transgenic model was created using Mest driven by a 
CAG promoter which can be activated by tissue-specific expression if cre-recombinase. Transgenic mice were placed 
on a chow diet and the organs and fat pads were harvested. RNA was isolated from these tissues and analyzed by qRT-
PCR in order to confirm that the transgenic model was tissue specific.  qRT-PCR analysis demonstrated that Mest
transgenic mice expressing Adipoq-cre positive mice resulted in the induction of Mest in adipocytes at a level 
consistent to mice fed a high fat diet.  Previous studies have shown that endogenous Mest is co-regulated with several 
genes including imprinted genes (Klf14) and genes associated with the Wnt (Sfrp5) and Tgf-B (Bmp3) signaling 
pathways. Using a transgenic model, we were able to confirm that Mest expression plays a role in regulating the 
expression of Sfrp5 in gonadal adipose tissue and brown adipose tissue, but not in inguinal adipose tissue. Slc5a7, a 
gene shown to be dowregulated in gonadal adipose tissue of Mest knockout mice was also shown to be up-regulated in 
mice overexpressing Mest . These studies show that this transgenic model will allow us to better understand the 
biological mechanism by which Mest functions as an epigenetic determinant of diet-induced obesity. 
HIGH FAT DIET
Epigenetics & Obesity 
Epigenetics is defined as the 
study of how changes in an 
organism’s physical or 
nutritional environment initiate 
biological mechanisms that 
bring about changes in gene 
expression, but not the 
underlying DNA sequence. 
Using an inbred, genetically 
identical, mouse strain, our lab 
seeks to understand the 
biological mechanisms and 
genes that function as 
epigenetic regulators for 
variable development of diet-
induced obesity. To characterize 
these epigenetic regulators, 
inbred mice were fed a high fat 
diet in a controlled environment 
to identify genes associated 
with variable body weight 
among individuals. Mest, an 
imprinted gene has been shown 
to be strongly correlated with 
increased body weight and fat 
mass gain. 
Highly variable induced  expression of Mest among genetically homogeneous mice when fed an 
obesogenic diet presents a strong correlation with an increase in body weight and in fat mass. The highest 
and lowest 10’th percentile of Mest expression was quantified by qRT-PCR in arbitrary units (AU) and 
normalized to cyclophilin. 
Tissues  from  transgenic mice were harvested and analyzed for Mest expression by qRT-PCR. Gene 
expression was measured in arbitrary units (AU) and normalized to TBP. Some founder lines were found 
to be more effective at overexpressing Mest than others .
Summary/Conclusions 
To better understand the function and regulation of Mest in adipose tissue expansion, we generated a conditional 
CAG-GFP-Mest transgenic mouse model that overexpresses Mest only in adipose tissue. 
• Analysis by qRT-PCR revealed that Mest overexpression in the transgenic model was specific to adipocytes and 
that it was at a level consistent with HFD-induced wild type Mest expression in inguinal and gonadal fat. 
• Expression of Sfrp5, and Slc5a7 was elevated in gonadal fat and brown fat, but not in inguinal fat. This increase 
was significant in Sfrp5 and Slc5a7 (p < 0.005) in brown fat, and in Slc5a7 (p < 0.05) in gonadal fat. 
• Mest transgenic mice also tend to have reduced expression of Ucp1 in gonadal and brown adipose tissue. 
These results suggest that Mest, or the consequence of elevated expression of Mest, plays some role in the 
function and regulation of several adipose genes such as Sfrp5, Slc5a7 and Ucp1. Further studies using a larger 
pool of age-matched mice and various dietary conditions, as well as mice with inactivation of Mest, will be valuable 
in determining how transgenic overexpression of Mest effects adipose tissue function.
University of Southern Maine – Maine Economic Improvement Fund (MEIF) , Dr. Robert A. Koza and Dr. 
Rea Anunciado-Koza , Professor David Champlin , Summer Student Research Program (MMCRI), Liz 
Bergst and Dr. Lucy Liaw , Dr. Pradeep Sathyanarayana and Dr. Aldona Karaczyn
MMCRI Transgenic core (Larisa Ryzhova, Lucy Liaw, Anne Harrington.) 
MMCRI Animal Facility 
Supported by pilot funding from P20GM121301 (COBRE; Liaw)
Mice with an adipose tissue specific inactivation of Mest created by crossing mice with a paternal 
floxed allele for Mest with Adipoq-cre transgenic mice reduced bodyweight gain and adiposity 
compared to littermate controls after being fed a high fat diet from 8 to 24 weeks of age. 
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Methods
Transfection of HEK293 cells CAG-GFP-Mest and CAG-GFP-Mest-Myc (A,B) and co-transfection of 
cells with CAG-cre recombinase (C,D) resulted in reduced GFP signal for CAG-GFP vectors. Cells 
were quantified by qRT-PCR.
Experimental Design
A tissue specific transgenic 
model was created using a 
CAG promoter with GFP 
inserted between two LoxP
sites. When crossed with a 
cre recombinase mouse, the 
GFP between  LoxP sites 
was removed resulting in the 
CAG promoter functioning to 
overexpress Mest. A 
conditional trasgenic model 
and a Mest-Myc fusion 
protein model were made 
using this method. 
Adipose-specific	inactivation	of	Mest
Results	
Characterization of various transgenic founder lines for Mest expression in gonadal, inguinal, and brown  
(BAT) adipose tissue . Gene expression was measured in arbitrary units (AU) and normalized with TBP. 
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Gene expression was 
measured in arbitrary 
units (AU) and 
normalized by TBP. We 
determined that mice 
with transgenic 
expression of Mest also 
showed elevated levels 
of Sfrp5 and Slc5a7 in 
gonadal fat and in brown 
fat only, and lower levels 
of Ucp1 that was most 
evident in gonadal fat. 
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Abstract 
Background: Neutrophils serve a critical function in the innate immune system by
maintaining a frontline defense against bacterial and fungal pathogens. New generations of
neutrophils as a result of increased myeloid progenitor cell proliferation in bone marrow in
response to severe infection is called emergency granulopoiesis. To maintain healthy
neutrophil numbers, the process of granulopoiesis is tightly regulated. Granulocyte colony-
stimulating factor (G-CSF) is a hematopoietic growth receptor that is the primary stimulator
for neutrophil production during emergency hematopoiesis. Janus kinase, signal transducer
and activator of transcription (STAT) pathway components are principle intermediates in the
G-CSF receptor signaling cascade. Jak2 is one of the key downstream kinases stimulated
by G-GCSF. Once phosphorylated, Jak2 activates STAT3 to be transported to the nucleus: a
cascade necessary for accelerating neutrophil production. During G-CSF-driven emergency
granulopoiesis, STAT3 is required to boost immature neutrophil numbers in bone marrow
and to regulate acute neutrophil mobilization.
Rationale: The signal transduction pathways that regulate emergency granulopoiesis are of
significant interest as G-CSF is used therapeutically to increase circulating neutrophil counts.
However, the underlying mechanisms directing G-CSF-responsive myeloid progenitor
expansion are poorly understood.
Podocalyxin is a transmembrane protein belonging to the CD34 family, and is widely
expressed in hematopoietic cells. Previously, our laboratory discovered that mice lacking
Podocalyxin (Podxl) had significantly elevated peripheral blood neutrophils following G-CSF
treatment. Therefore, the long-term goal of this project is to understand how Podxl regulates
granulopoiesis and functional maturation of neutrophils in bone marrow. In this study, we
investigated whether loss of Podxl affects i) basal activity of STAT3 in myeloid progenitors,
and ii) activity of STAT3 in the emergency granulopoiesis due to response to G-CSF
administration.
Experimental Strategy: Mice, lacking the Podxl gene in their hematopoietic cells, were used
in this study. Effects of Podxl deletion on myeloid progenitor (GMP) cell production during
homeostasis and G-CSF-driven emergency response were assessed. Flow cytometry
analyses were applied to investigate phosphorylated levels of STAT3 in GMPs from wildtype
(WT) and Podxl conditional hematopoietic knock-out (cKO) mice injected with PBS or G-
CSF.
Results: We found that loss of Podxl reduces activity of STAT3 during emergency
granulopoiesis and homeostasis. These results coincided with reduced number of the GMP
population in both Podxl cKO mice injected with G-CSF and those injected with PBS,
suggesting that Podxl deletion restricts GMPs’ differentiation.
Conclusions: Podxl promotes positive effects of STAT3 in the granulocytic lineage that directs
G-CSF-responsive myeloid progenitor proliferation.
Future Studies: We hope to investigate whether i) loss of Podxl affects myeloid progenitor’s
cell-cycle progression and maturation in response to G-CSF, and if ii) Podxl regulates
neutrophil trafficking during emergency granulopoiesis.
Discussion and Conclusions 
Methods 
Podocalyxin Promotes Activation of STAT3 Signaling Pathway in Emergency 
Granulopoiesis
Jahanara Freedman1,2, Aldona Karaczyn1 and Pradeep Sathyanarayana1
1Center for Molecular Medicine, Maine Medical Research Institute, Scarborough, Maine 2 Wellesley College, Wellesley, Massachusetts
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Figure 3: Loss of Podxl reduces frequency of GMPs during homeostasis and G-CSF-induced stress
granulopoiesis. A] Representative gating strategy of lineage negative c-kit positive Sca-1 negative
compartment containing myeloid progenitors and subsequent characterization of GMP population between Podxl
cKO and WT mice treated with either PBS or G-CSF. In bone marrow, lineage negative population, c-kit, and
sca-1 were used to identify myeloid progenitor compartment, and CD34 and CD16/32 antibodies were used to
identify GMP populations. Experiments were performed three times. (N=4, N=8, N=8). Both plots were collected
using FlowJo. B] Frequency of GMP population between Podxl cKO and wildtype mice treated with either PBS
or G-CSF. Statistical significance was performed using the Student’s Two-Tailed T-Test for Significance. *p<0.05
**p<0.01 ***p<0.001
**
Figure 1: Flowchart diagram portraying 
experimental design
Figure 5: Model of Podxl’s role in G-CSF induced Emergency Granulopoiesis. Upon G-CSF (left panel),
Podxl is hypothesized to promote Jak2/STAT3 pathway. Jak2/STAT3 pathway consists of intracellular signaling
cascades that control demand-driven neutrophil production. Briefly, G-CSF phosphorylates transmembrane
protein Jak2 which then phosphorylates STAT3. Newly activated STAT3 enters nucleus to activate transcription
factors to promote reactive granulopoiesis, leading to production of neutrophils. Podxl’s absence in hematopoietic
systems (right panel) leads to decreased GMPs production in bone marrow, with concomitant drop in mature
neutrophils (data not shown). Loss of Podxl results in elevated accumulation of neutrophils in blood. The reason
for the increase in neutrophil levels in the absence of Podxl during GCSF-induced response remains to be
elucidated.
Figure 2: G-CSF induces GMP proliferation and STAT3 activation in vivo. Lineage negative c-kit positive,
Sca-1 negative compartment (KL) containing myeloid progenitors from wildtype mice injected with either G-CSF
or PBS, N=4. To characterize GMP population, CD34 and CD16/32 antibodies were used. GMP compartments
were further analyzed to show expression of phosphorylated STAT3 [A] or un-phosphorylated STAT3 [B]
expression between groups. Anti-STAT3-PE, phospho-STAT3 PE and isotype control-PE antibodies were also
used. Plots were collected using FlowJo. Statistical significance was performed using the Student’s Two-Tailed
T-Test for Significance. *p<0.05 **p<0.01 ***p<0.001.
We used Podxl conditional knock out (cKO) mice model generated using the flox-Cre technique to
delete the expression of Podxl in hematopoietic lineages. Wildtype and Podxl cKO mice were
injected with 125 µL/g G-CSF twice in two days to induce emergency response in hematopoietic
system. Initially, induction of myeloid progenitors (GMPs) were tested in wildtype and wildtype G-
CSF treated animals. Tested groups included wildtype(WT),
wildtype with G-CSF(WT G-CSF), Podxl cKO(cKO), Podxl
cKO with G-CSF(cKO G-CSF). Bone marrow(BM) from the
tibias and femurs was collected. BM cells were flushed with
IMDM medium supplemented with 2% FBS and antibiotic
and centrifuged. BM cells were passed through 21G syringe
and 0.45 micron strainer. 0.5% Bovine Serum Albumin
buffer and PBS 1x was added to the cells to be centrifuged.
Cells were counted using hemocytometer. Red blood cells
were removed by chemical lysis. Single cell suspension of
BM cells was processed by EasySep Mouse Hematopoietic
Progenitor Cell Isolation Kit according to manufacturer’s
protocol (StemCellTechnologies). Lineage negative popula-
tion was obtained using immuno-magnetic separation. Number of lineage negative cells was
evaluated. One million cells were blocked with rat and rabbit IgG and labelled by antibodies(C-kit,
Sca1, CD16/32, CD34) followed by fixation and permeablization. Phospho-STAT3, STAT3, and
isotype IgG antibodies were added separately to tested groups and incubated for one
hour. Samples were submitted to flow cytometry for analysis. Flow cytometry data analysis was
performed using FlowJo.
B]
Figure 4: Loss of Podxl reduces activity of STAT3 signaling during homeostasis and G-CSF- induced
emergency granulopoiesis. The same experimental and data analysis approach and gating strategy was used
as described in Figure 3. Anti-STAT3, phospho-STAT3 PE and isotype control antibodies were also used.
Statistical significance was performed using the Student’s Two-Tailed T-Test for Significance. *p<0.05 **p<0.01
***p<0.001. (N=4, N=8, N=8).
A] B]
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We found that absence of Podxl in GMPs reduces activity of STAT3 on basal level and in G-CSF-induced
response. This negative effect of Podxl deletion on STAT3 phosphorylation coincided with markedly reduced
number of GMPs. We found no difference in the total level of STAT3 in G-CSF-treated Podxl cKO as compared
to wildtype mice, however total levels of STAT3 were increased in Podxl cKO in steady-state, suggesting an
existence of regulatory feedback. Studies have shown that in steady state, STAT3 serves a negative regulatory
function by suppressing accumulation of neutrophils in blood1. This activity is attributed to STAT3-dependent
regulation of a feedback inhibition of G-CSFR signaling. We recently found that Podxl deletion increases
accumulation of the immature myeloid subpopulation with the associated drop in mature neutrophils in the bone
marrow, and increased levels of neutrophils in blood. We found that Podxl-deficient GMPs showed suppressed
G-CSF–responsive growth relative to wild-type cells, however the underlying cellular response such as
enhanced rate of differentiation of GMPs remained unclear. To conclude, our findings suggest that Podxl
promotes the activation of STAT3 in the granulocytic lineage that directs G-CSF-responsive myeloid progenitor
proliferation. In the future, we hope to explore the effects of the loss of Podxl on myeloid progenitor’s cell-cycle
progression and maturation in response to G-CSF. We also hope to investigate if Podxl regulates neutrophil
trafficking during emergency granulopoiesis.
Results 
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Relationship Between Travel Distance to Cancer Care Center 
and Outcomes in Ovarian Cancer
Jonathan Emery, Lee Lucas PhD, Leslie Bradford MD
Aim
The purpose of this investigation is to determine whether there is 
an association between proximity of patients to a comprehensive 
cancer center and mortality in ovarian cancer patients. 
Introduction
In 2015, there were 1.2 million women with ovarian cancer, which 
resulted in 161,100 deaths worldwide. Ovarian cancer is the 
seventh-most common cancer, and the eighth most common cause 
of death from cancer. In Maine, 14,070 women are expected to die 
from this disease in 2018.
There is evidence that high volume facilities produce better 
outcomes for patients. This has led to an argument in favor of the 
regionalization of medical facilities. A possible drawback of this 
strategy is an increase in travel distance for patients. To begin 
weighing the pros and cons of regionalization it is worth asking: 
Does travel distance affect mortality?
Methods
Data from 2004 through 2015 were abstracted from the National 
Cancer Database (NCDB), a nationwide oncology registry with 
information on more than 70% of incident cancers in the United 
States. The study cohort included 165,674 patients and were 
limited to those with an invasive diagnosis, treated at a reporting 
facility, and not missing data for travel distance or stage. 
Study Variables
PREDICTIVE VARIABLE:
Travel Distance
NCDB includes a variable, 
CROWFLY, which is an 
estimation of the distance 
between the ZIP code of the 
patient’s residence and the 
facility. In this analysis, we split 
the travel distance into 
quartiles so that about 25% of 
the patients were within each 
distance range as follows: 
Q1: < 5.2 miles 
Q2: 5.2 – 11.9
Q3: 12 – 31.1
Q4:  > 31.1
OUTCOME VARIABLE:
30 Day Mortality
NCDB includes a binary variable, 
which tells whether a patient has 
died 30 days after their diagnosis. 
Covariates
- Age
- Race/Ethnicity
- Stage
- Comorbidity score
- Type of Cancer Center
- Income
- Education
- Insurance
- Facility volume
Exclusion Criteria
National Cancer Database
Ovarian cancer instances
2004-2015
(N=194,828)
Non-invasive ovarian cancer
(N=1,151)
Invasive ovarian cancer
(N=193,677)
Patients treated in 
non-reporting facility
(N=8,786)
Patients treated in 
reporting facility
(N=184,891)
Patients missing stage
(N=16,805)
Patients missing travel distance
(N=2,412)
Final Cohort
(N=165,674)
Baseline Characteristics of Cohort
1st 
quartile
4th 
quartile Chi-square
(n = 
41,446)
(n = 
41,390) p-value
Age <.0001
< 40 2509 (6) 2565 (6)
40 - 49 4887 (12) 5177 (13)
50-  59 9054 (22) 10420 (25)
60 - 69  9570 (23) 11601 (28)
70 - 79  8551 (21)  8294 (20)
> 80  6875 (17) 3333 (8)
Charlson-Deyo score <.0001
0 32243 (78) 33496 (81)
1 7048 (17) 6268 (15)
> 2 2155 (5) 1626 (4)       
Insurance <.0001
Uninsured 1706 (4) 1756 (4)
Private 17480 (42) 18507 (44)
Medicaid  3093 (7) 2571 (6)
Medicare 18271 (44) 16705 (40)
Other 259 (1) 545 (1)
Median income in patient’s ZIP code <.0001
 < 38,000$ 8115 (20) 10179 (25)
38,000$ - 47,999$ 9017 (22) 14017 (34)
48,000$ - 62,999$ 10289 (25) 10771 (26)
> 63,000$ 13997 (34) 6345 (15)
No high school degree in patient’s ZIP code <.0001
> 21% 7497 (18) 8388 (20)
13% - 20.9% 9122 (23) 13037 (32)
7% - 12.9% 13026 (31) 13729 (33)
< 7% 11186 (27) 6197 (15)
Facility Type <.0001
Community Cancer Program 3906 (10) 715 (2)
Comprehensive Community Cancer Program 17852 (46) 13412 (35)
Academic/Research Program 12849 (33) 21203 (55)
Integrated Network Cancer Program 4330 (11) 3495 (9)
Rurality <.0001
Metro 39334 (97) 21703 (54)
Small Urban 1043 (3) 6349 (16)
Rural 212 (1) 9915 (25)
Isolated Rural 5 (0) 2387 (6)
Stage <.0001
1 9920 (24) 9647 (23)
2 3715 (9) 3877 (9)
3 15902 (38) 19395 (47)
4 11909 (29) 8471 (20)
Mean facility volume per year <.0001
< 11.6 16634 (40) 4600 (11)
11.6 - 25.08 11180 (27) 8945 (22)
25.09 - 39.67 8414 (20) 10515 (25)
> 39.67 5218 (13) 17330 (42)
Characteristic
Conclusion
After controlling for covariates, we can say that, overall, travel 
distance does not have a statistically significant relationship with 
30 day mortality among ovarian cancer patients. The next step, 
for a more in depth look at this question, would be to examine 
patients who travel further specifically to higher volume facilities 
in comparison to those who travel shorter distances to lower 
volume facilities and then to see if any effect is statistically and 
clinically significant. 
Percent of Patients Treated at Each Type 
of Cancer Center by Distance. 
Results
Lower mortality Higher mortality
Multivariable logistic regressions were performed to obtain odds ratios for each category distance compared to 
the first quartile (Q1) as reference. Before controlling for covariates we saw significantly lower odds of mortality 
with longer travel distances. Without covariates we found: Q2 Odds Ratio (OR), 0.884 [95% CI, 0.788 to 0.991], 
Q3 OR, 0.724 [95% CI, 0.643 to 0.816], Q4 OR, 0.891 [95% CI, 0.797 to 0.997]. 
With covariates, we lost some of these significant odds ratios: Q2 OR, 1.042 [95% CI, 0.925 to 1.175], 
Q3 OR, 0.881 [95% CI, 0.777 to 0.999], Q4 OR, 0.952 [95% CI, 0.841 to 1.077].
Odds Ratios
Q1 vs Q2
Q1 vs Q2
Q1 vs Q2
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 Focality and Co-infection of Powassan Virus (Lineage II) within a Population of Ixodes 
scapularis Ticks in Wells, ME 
Powassan virus (Flaviviridae: Flavivirus) is a vector-borne 
disease that circulates in parts of North America and Russia in 
two serologically-indistinguishable lineages:  lineage I (POWV) 
and lineage II (deer tick virus [DTV]).  This study looked at DTV.  
•  Recent evidence suggests DTV may exhibit nidality, meaning 
it exists in small microhabitats (foci) consisting of just the right 
mixture of environmental factors for the virus to propagate.2  
•  Exists primarily in a zoonotic cycle between Ixodes 
scapularis ticks (deer ticks) and small-medium mammals (e.g. 
the white-footed mouse, woodchucks, and skunks).7 
•  ~10% of POWV human infections result in deadly encephalitis 
and 50% result in long-term neurological sequelae.7 
•  In the United States there has been a threefold increase in 
human infections in the past two decades (27 cases from 
1958-1998 and 85 cases from 2003-2017), which may be due 
to rising deer tick populations in parts of North America.5,7 
•  Ticks can be co-infected with other vector-borne diseases 
such as the agents of Lyme, anaplasmosis, babesiosis, and 
tick-borne relapsing fever.1 
More southern counties in Maine reportedly have higher DTV 
infection rates compared with those in the north. This study was 
conducted in York County, which had an adult deer tick infection 
rate of 2.27% in the fall of 2017. 
Keenan Ernste, Kyle Timmer, Rebecca Robich, Susan Elias, Charles Lubelzcyk, Elisabeth Henderson, Danielle Cosenza, Margaret Welch, Robert Smith 
Vector-Borne Disease Laboratory – Maine Medical Center Research Institute 
•  Investigate nidality by collecting ticks from five different 
habitat types and testing them for DTV to determine what 
constitutes a good pathobiocenose. 
•  Determine what percentage of DTV-infected ticks were 
also infected with Lyme, anaplasmosis, babesiosis, and/or 
tick-borne relapsing fever. 
Methods Background Results Discussion 
References 
Field Collection 
•  Flagged for ticks in ten transects (5 different habitat types) in 
the Wells National Estuarine Research Reserve in Wells, 
ME.  Each transect made up of ten consecutive 10x1m plots. 
 1.  Forest with invasive shrub species in the understory 
 2.  Forest with sparse, native shrub species in the Understory 
 3.  Edge (forest-field intersection) 
 4.  Shrub (little-to-no tree cover) 
 5.  Field (grassland) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2:  Left image is an example of the flagging procedure for tick collection.  
The right image shows female (F) and male (M) adult deer ticks 
 
Laboratory Testing 
•  Ticks were ground in PBS solution and aliquots of these were 
tested in pools (10 adults/pool, 20 nymphs/pool, and 50 
larvae/pool) by RT-PCR, amplifying the NS-5 gene (806bp). 
•  Individual ticks from positive pools were then tested using the 
same RT-PCR protocol and any positives were confirmed by 
genomic sequencing 
•  To determine rate of co-infection, DTV-positive ticks were 
then tested for B. burgdorferi, A. phagocytopylum, B. microti, 
and B. miyamotoi by PCR assay. 
  
The majority of nymphal and adult ticks were collected from a 
deciduous forest habitat with an understory mostly composed of 
invasive species of plants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3:  Bar graph showing the number of ticks/hr by habitat type.  The most adults and nymphs 
were collected from the forested habitats with invasive shrub species in the understory 
 
An ArcGIS hotspot analysis tool identified, with 99% confidence, 
that areas within transect 3 (forest with invasive shrub species 
in the understory) may have been “hotspots” (focal transmission 
sites) for DTV.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Co-infection PCR assays revealed that seven out of the ten total 
DTV-positive ticks (70%) were also infected with B. burgdorferi 
(Lyme). None of the DTV-positives were also infected with A. 
phagocytophylum, B. microti, or B. miyamotoi.   
This study investigated Powassan virus nidality and co-
infection within Ixodes scapularis ticks in Wells, ME by 
collecting 373 ticks and using PCR assays and genomic 
sequencing to test for DTV.  Positive ticks were also tested for 
co-infection with B. burgdorferi, A. phagocytophylum, B. 
microti, and B. miyamotoi. 
 
•  This novel finding indicates possible nidality (focality) for 
DTV that corresponds with habitats known to be favorable 
for deer ticks (i.e. deciduous forest with invasive shrub 
species in the understory).  Therefore, invasive shrubs, like 
barberry, may play a role in forming DTV-favorable 
pathobiocenoses.  However, differences in sample sizes 
between transects means we need to exercise caution 
when extrapolating this data. 
 
•  The habitat type in which the most ticks were collected, 
deciduous forest with invasive shrub understory, is 
consistent with previous research.8  This is thought to be 
because some invasive shrub species are resistant to deer 
browsing, act as good habitats for small mammals, and 
provide shade for ticks6. 
 
•  Our reported 2.7% infection rate is within the 0.6-5% range 
expected from previous reports.3  The actual infection rate 
may be higher because this study primarily took place 
during peak nymphal season, and nymphs may have lower 
infection rates than adults (unpublished data). 
 
•  Also similar to previous reports, only lineage II (DTV) and 
not lineage I (POWV) was found in I. scapularis ticks.2,3,7 
 
•  The 70% positivity rate for DTV and B. burgdorferi (Lyme) 
co-infected ticks corresponded with reports on Lyme 
infection rates in Wells, ME (annual CDC report 2012). 
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Results 
Out of 373 total ticks tested, 10 adults were positive for DTV, 
making the overall infection rate 2.7%.  Eight of the positive 
ticks came from a deciduous forest habitat with invasive plant 
species, namely Japanese barberry, in the understory. 
Table 1.  Field Site Characteristics and Collection Results 
Transect Number Habitat Type Number of Ticks (%) 
Number of DTV 
Positives 
Transect 1 
Brush 
23 (6.2) 1 
Transect 2 2 (0.5) 0 
Transect 3 Forest with Invasive 
Understory 
106 (28.4) 6 
Transect 4 113 (30.3) 2 
Transect 5 
Field 
6 (1.6) 0 
Transect 6 10 (2.7) 1 
Transect 7 
Forest/Edge 
14 (3.8) 0 
Transect 8 21 (5.6) 0 
Transect 9 Forest with Native/
Sparse Understory 
67 (18.0) 0 
Transect 10 11 (2.9) 0 
Total 373 10 
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Ticks per Hour by Cover Type, WNERR, 2018 
Adults 
Nymphs 
Life Stage Number of Ticks Collected 
Number of DTV 
Positives (%) 
Adult 180 10 (5.6) 
Nymph 142 0 (0) 
Larvae 51 0 (0) 
Total 373 10 (2.7) 
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Objectives 
Hypotheses 
•  DTV-infected ticks will exhibit nidality (focality), meaning 
they will tend to exist within certain microhabitat-types 
more than others. 
•  Co-infection will be observed in ticks infected with DTV. 
1 
2 
3 
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7 
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5 
4 
9 10 
Fig. 3:  Hotspot analysis of transects.  Transects are numbered and dots represent 
plots within transects.  The red dots from transect 3 indicate hotspots identified with 
99% confidence and white dots indicate plots that were not identified as hotspots   
Fig 1:  Left image is a map of human POWV/DTV infections in Maine 
and the right image is showing prevalence of POWV-infected deer ticks   
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Characterization of the Proteolytic Processing of CTHRC1
Kimberly L. Drew1, Qiaozeng Wang MS1, Yong-Ri Jin PhD1, and Volkhard Lindner MD,PhD1
1Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine
Introduction:
Methods:
Collagen Triple Helix Repeat Containing 1 (CTHRC1) is a hormone that is 
currently being researched in the biomedical field for its role in a variety of 
different health interests, including, but not limited to cancer, heart disease, 
inflammatory response, metabolism, bone growth and aging1,2,3. As CTHRC1 is 
a versatile hormone, the proteolytic processing of this hormone, and where it 
is active and secreted are essential information to be able to use CTHRC1 to 
further the understanding of its role in these complex medical interests. The 
proteolytic processing of CTHRC1 is not clearly understood, specifically 
whether or not the hormone needs to be activated and if it does; how it is 
activated and secreted.  CTHRC1 is expressed in neuroendocrine cells, which 
require regulated secretion to be activated and this led to further conclusions 
that CTHRC1 might require activation and regulated secretion as well. As 
CTHRC1 has a c-terminal lysine, literature on the POMC processing pathway, 
which involves carboxypeptidase E (CPE) cleaving the c-terminal lysine, gave 
way to a possible mechanism that could be explored to understand the 
proteolytic processing of CTHRC14,5. To characterize this possible mechanism, 
six cell lines were transfected with four different plasmids, and the 
conditioned medium and cell lysate were immunoblotted to observe 
secretion, possible truncations to the hormone, and presence of 
CTHRC1. These cell lines were also immunoblotted for endogenous CPE, 
resulting in two further experiments to understand the impact of CPE, these 
included: observation of cell line that expressed endogenous CPE (AtT20) and 
the second being the observation of one that does not (293-T) to understand 
the ways that CPE influences secretion in these cells. 
Results: Results: Summary and Conclusions:
Acknowledgements:
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The POMC processing pathway 
occurs in the hypothalamus and 
the pituitary and is an essential 
pathway in the creation of ACTH 
and alpha MSH.4,5 In this pathway, 
there is the cleavage of the c-
terminal lysine from the hormone, 
which is a possible mechanism for 
the activation and secretion of 
CTHRC1. As CPE is expressed in the 
pituitary, and CTHRC1 is as well, this 
appeared to be a possible 
candidate for the cleavage, and 
ultimately secretion and activation 
of CTHRC1.6,7 
Transfection: The six cell lines were transfected with various plasmid using XTreme Gene 9 
Transfection Reagent. The cells were transfected when they were around 50-70% confluent 
for 72h before harvested. The plasmids used were:
- hFL ( human CTHRC1 full length)
- hFLΔK(human CTHRC1 without the terminal lysine)
- VVD (human CTHRC1 missing propeptide section of N-terminus)
- 502mychis (rat CTHRC1 with myc tag)
- CTHRC1 7his (human CTHRC1 with his tag)
Western blotting was completed using a 15% separating gel and 5% stacking gel, 15 
microliters of each conditioned medium sample were loaded as well as 100 micrograms of 
the cell lysate and were transferred to a Bio-Rad PVDF 0.2 millimeter membrane (A280 
protein reading was used to determine the OD of each). 
Figure 3 .293-T transfected cells portray CTHRC1 in the cell lysate and does not secrete into the 
conditioned medium. Western blotting of transfected 293-T cells with four plasmid constructs hFL, 
hFLΔK, VVD, and 502mychis, as well as the negative control of cells that were not transfected. 
The conditioned medium (CM) and cell lysate (CL) were harvested, probed with the Vli55 
antibody, and detects the presence of CTHRC1 around 30 kDa. The immunoblotting shows a 
lack of secretion of the CTHRC1 into the conditioned medium, which could be due to the 
nonexistence of CPE in the cells. 
Figure 8. 293-T cotransfected cells with CPE do not show clear secretion of CTHRC-1 into the conditioned 
medium. Western blotting of cotransfected cells with plasmid CPE and indicated plasmid (hFL, hFLΔK, VVD, 
502mychis), as well as plasmid EGFP and a second indicated plasmid as a control, were harvested in samples 
of conditioned medium (CM) and cell lysate (CL). The probing of these blots with Vli55 and 13E9 as indicated 
show that there is minimal secretion of CTHRC1 around 30 kDa into the CM as shown, and a continued 
presence in the CL, with no clear increase with CPE. Note the shift between the CPE+ hFLΔK CL and EGFP+
hFLΔK that indicates a post-translational modification that is only occurring with CPE that is causing the sample 
to move more slowly across the membrane. In the left blot, those cotransfected with hFL have the highest 
secretion into the CM, notably that with CPE, although it is not as significant as expected. There is also a shift 
between the 502mychis transfected cells that have the myc tag versus the plasmids that do not.
Figure 7. Cotransfection of 293-T cells with indicated plasmid and CPE does not appear to 
secrete a higher amount of CTHRC1 in the conditioned medium. Most of the with CPE have 
higher amounts of CTHRC-1 in the CM, although it is not a significant amount and in the case 
of hFLΔK, that without CPE has a higher amount of CTHRC1 according to the OD450 read from 
the plate reader than that with CPE. 
Figure 4. 293-T cells transfected with rFLmychis show 
secretion of CTHRC1. Western blotting of the 
conditioned medium (CM) and the cell lysates (CL) of 
transfected cells with plasmid rFLmychis as indicated 
and those with plasmid GFP as a control. These 
samples were probed with various CTHRC1 
antibodies, as indicated on the side of each blot. 
Several of the blots show the secretion into the CM, 
as well as two bands in the CM, which shows a fully 
post-translationally modified sample as well as that 
which has not been fully modified. 
Figure 5. 293-T cells transfected with hFL show 
minimal secretion of CTHRC1. Transfection of 293-T 
cells with plasmid hFL as indicated and those with 
plasmid GFP as a control were harvested as 
conditioned medium (CM) and cell lysate (CL) 
samples. The membranes were probed with 
various CTHRC1 antibodies, which indicated some 
secretion of CTHRC1 into the CM, as well as high 
prevalence in the CL. The control indicates non-
specific bands that are around 30 kDa as well, 
although the strength of the band differs and does 
not conclude that these bands are nonspecific in 
the hFL transfected samples.
Figure 10. Expression of CPE is 
significantly higher in human smooth 
muscle cells compared to human 
endothelial cells. This qRTPCR data shows 
a high level of expression of CPE in the 
smooth muscle cells and a minimal 
amount in the human endothelial cells.
Figure 9. Mouse brain, bone and joint, heart, 
and cortical have high expression of 
CPE. Results from qRTPCR detail a high 
expression of CPE in the mouse brain, as 
expected, as well as fairly high levels in the 
mouse bone (includes joint and 
cartilage). There is also a high level of 
expression in the mouse heart and 
cortical(without bone marrow). The mouse 
embryonic fibroblast, endothelial cells, and rat 
CAT (carotid artery injury vessel), have low 
expression, with the mouse tibia (without bone 
marrow) resulting in the lowest 
expression. These results correlate with known 
research on the location of CPE, with notably 
high amounts in the mouse brain.
Figure 11. Carboxypeptidase E (CPE) is endogenously 
expressed in AtT20 cells. Western blotting of cell 
lysates of all six cell lines not transfected and probed 
with anti-carboxypeptidase E antibody shows a clear 
detection of CPE around 50 kDa in AtT20 cells, a 
minimal detection in NIH3T3 and EC cells, and no 
detection in the remaining three cell lines.
Figure 12. Transfected CHO cells shows detection of CTHRC-1 in the cell lysate and some 
conditioned medium, as well as the indication of a shift between the cell lysate and cell 
medium. CHO cells transfected with the plasmids hFL, hFLΔK, VVD, and 502mychis as 
indicated, and were collected as samples of conditioned medium (CM) and cell lysate 
(CL) and the presence of CTHRC-1 was detected around 30 kDa. The membranes were 
probed with various CTHRC1 antibodies. There are a series of shifts that are observed in 
these cells, including that of the cells transfected with the plasmid that has the myc tag did 
not migrate as quickly across the gel as the others, and those with the VVD plasmid that is 
missing an epitope travels further. There is also another notable shift shown in the B) 
diagrams in which there is a shift between the hFL and hFLΔK where the CM did not travel 
as quickly as the CL and may indicate a possible modification during secretion. 
Figure 6. Transfected AtT20 cells that express CPE endogenously indicate modification between cell lysate 
and conditioned medium. Western blotting of transfected AtT20 cells with hFL, hFLΔK, VVD, and CTHRC1 7his 
plasmid samples conditioned medium (CM) and cell lysate (CL), indicates minimal detection of CTHRC1 
around 30 kDa aside from the hFLΔK transfected cells. These samples indicate a shift in the CTHRC1 samples 
along the membrane in the CL and CM, which could be explained by the presence of CPE(expressed 
endogenously). The controls indicate nonspecific bands that are similar to the bands that show the presence 
of CTHRC1, which makes it difficult to read.  
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Figure 2. Schematic of CTHRC1 amino acids showing the CTHRC1 antibodies detections along 
the protein.  
Figure 1. Schematic of the POMC processing pathway 
in the hypothalamus from Bicknell et all.5
A
B
kDa
α-Vli5525--
Results:
1. 293-T cells do not secrete CTHRC1 efficiently, even with 
the addition of CPE.  
2. In the cell lysates, the lower, distinct band is the non-
glycosylated version, whereas the fuzzy upper band is 
the glycosylated version.  
3. In the AtT20 and CHO cells transfected with hFL and 
hFLΔK there was the indication of a slightly larger 
band(s) in the conditioned medium of hFL and hFLΔK, 
than that of the cell lysate.  This indicates a further post-
translational modification that occurs outside of the cell 
with these plasmids.  
4. Depending on the cell line, the monoclonal CTHRC1 
antibodies that were used show nonspecific bands that 
are specific to that individual cell line.  
5. In the AtT20 cell transfection Western Blot there is no 
secretion outside of the cell especially with the 
difficulties in reading the Western Blot due to the 
nonspecific bands at a similar size, which was 
unexpected.  Assuming that there were no difficulties 
with the transfection that indicates that this construct is 
only minimally able to be secreted. 
6. Previous results under mass spectrometry determined 
that CHO cells CM has its c-terminal lysine, and so the 
result of CHO not having expressed endogenous CPE 
does not disprove the hypothesis.  
7. Notably in the CHO transfection, the samples 
transfected with 502mychis, show no shift between the 
CM and CL. This may be explained by the c-terminal tag 
influencing the post-translational modifications that take 
place outside of the cell.  
8. Along with this observation, the rFLmychis Western Blot 
that exhibits the secretion of the CTHRC1 into the CM in 
293-T cells may indicate that the c-terminal lysine 
interferes with the ability for 293-T cells to secrete 
CTHRC1 efficiently.  
9. In the 293-T cells when cotransfected with CPE+hFLΔK, 
the top band is significantly higher than that without CPE 
and appears to be a trimer, which is unlikely after the 
denaturing involved in Western blotting.  This observation 
currently does not have a conclusion aside from the 
possibility that the trimer is covalently cross-linked, but will 
continue to be explored in future experiments.  
10. Mass spectrometry will be necessary to finalize these 
observations in the future, as this will allow us to 
determine where truncations are and whether or not it is 
likely that this is caused by CPE.    
α-Vli55
α-13E9
13E9 detects an unknown epitope 
between the N terminus and C 
terminus
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Genetic Testing in Hospitalized Children with ASD: Prevalence and Influences  
Margaret Meserve1,  Briana Taylor 1,2, Christine Peura1,2, Matthew Siegel1,2 
for the Autism and Developmental Disorders Inpatient Research Collaborative (ADDIRC) 
 
 The American College of Medical Genetics, 
American Association of Pediatrics, American 
Association of Psychiatry, and other medical 
governing bodies recommend that all children with 
ASD are referred for genetic testing.1  
 
 Unfortunately, these clinical recommendations are 
not reflected in practice throughout the ASD 
population.1,2 
 
 Children with ASD seeking care in inpatient 
psychiatric units could benefit greatly from genetic 
testing due to the complex natures of their 
diagnoses and behavior, which often include lower 
verbal  levels, intellectual disability, self-injurious 
behavior and emotional dysregulation.3 
 
Conclusions 
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Results Introduction Results 
 936 participants with ASD confirmed by direct 
assessment using the Autism Diagnostic Observation 
Schedule (ADOS) were recruited from the Autism 
Inpatient Collection3, a study conducted in 6 child 
psychiatric units in the US specializing in treatment 
of ASD.  
  207 were excluded due to missing information or 
inconclusive data (N = 729). 
 Parents filled out a Demographic and Medical Intake 
Form at admission which included questions 
regarding previous treatment, family history and 
other medical history.  
 Parents also filled out an Aberrant Behavior 
Checklist – Community form at admission, scoring 
their child on 5 subcategories of  behaviors from 0 = 
never a problem to 3 = severe problem. 
 Bivariate logistic regressions were conducted to 
examine the of parent reported genetic testing in 
hospitalized children with ASD. 
 
 
 1 2 3 4 5 6 7 
 43.07% of parents reported having genetic testing for 
their child prior to their admission.  
 25.6% received a significant result from this testing. 
 A significant result consists of any disorder or 
mutation found regardless of correlation to ASD. 
• 69.66% of parents with a significant result reported 
that genetic testing resulted in some “other” finding 
and 15.7% reported a Fragile X diagnosis.  
• Of the Other results, 9.68% were disorders known to 
have ASD etiology4 and 8.06% were considered ASD 
candidate genes5. 
Objectives 
 To examine the prevalence and findings of genetic 
testing in an inpatient community of children 
diagnosed with ASD. 
 
 To look for potential factors within demographics, 
medical history, family history and behavior that 
could influence access, referral and reporting of 
genetic testing.   
Demographic Genetic Testing 
(N=314) 
No Genetic 
Testing 
(N=415) 
Statistics 
Age (Years) (M/SD) 13.32 (3.45) 12.6 (3.34) P = 0.204 
Sex (Male) (N/%) 238 (75.7%) 350 (84.3%) X2 = 8.36 
p = 0.004 
ADOS Module (N/%) 
  1 
  2 
  3 
  4 
 
143 (45.5%) 
44 (14%) 
96 (30.5%) 
31 (9.87%) 
 
135 (32.5%) 
40 (9.6%) 
181 (43.6%) 
59 (14.21 %) 
X2 = 21.63 
p = 0.000 
Parental Education 
(N/%) 
  HS or Less 
  At Least Some College 
 
65 (21.4%) 
238 (78.5%) 
 
103 (24.9%) 
309 (75.1%) 
X2 = 1.22  
p = 0.269 
Adopted (N/%) 38 (12.1%) 36 (8.67%) X2 = 2.30 
p = 0.129 
Household Income 
  Less than $80,000 
  $80,000 - $160,000 
  More then $160,000 
 
186 (62.6%) 
77 (25.9%) 
34 (11.4%) 
 
282 (72.3%) 
94 (24.1%) 
14 (3.5%) 
X2 = 17.44  
p =0.000 
Table 1: Demographic Characteristics of 729 
Children with Autism Hospitalized in a Specialized 
Inpatient Unit 
Figure 1: The Rate of Genetic Testing  Within an 
Inpatient Population.  
Figure 2: Breakdown of the most common parent 
reported genetic testing results.  
Results 
 Of the total child sample, 588 (80.6%) were male and 
the average age was 12.9 (SD = 3.3). 
 436 (54.3%) children were non- or minimally- verbal 
(determined by ADOS Module administered).  
 There were statistically significant differences in 
gender, ADOS module, and household income 
between the two genetic testing groups  
 Those with genetic testing were more likely to be 
non- or minimally-verbal, and have a household 
income of more than $160,000. 
 
Figure 3A-C: Health , Behavioral, and 
Demographic Influences on Genetic Testing 
B 
A 
c 
 Families with a history of bipolar disorder (p = 0.006) 
were 74.1% more likely to report testing, while 
families with a history of a genetic condition (p= 0.00) 
were 78% times less likely.  
 Participants whose child was female were 71% more 
likely to report genetic testing (p = 0.004). 
 Participants whose child was nonverbal (p = 0.005) or 
minimally verbal (p = 0.018) were 201% and 209% 
more likely to report genetic testing. 
 Families with an income of less than $80,000 (p = 
0.00) or $80,000 - $160,000 (p = 0.002) were 72.8% 
and 66.7% less likely to report genetic testing. 
 
 Higher ABC sub-scores in Lethargy (p = 0.003) 
indicated a lower likelihood of reporting genetic 
testing and higher scores in Stereotypy (p = 0.017) 
indicated a higher likelihood of testing. 
 Children seeking care in an inpatient psychiatric 
facility received genetic testing at a higher rate than 
the general ASD community(<40%), 1,2 although the 
diagnostic yield for these tests matched the national 
standards (10-40%).1,5 
 
 Access to genetic testing and it’s findings could 
greatly influence the course of care in this 
population as it reveals important distinctions in 
disorders and ASD subtypes.   
 
 These results suggest that family medical history, 
child behavior, and demographic characteristics  
predict likelihood of genetic testing. These 
predictors may represent pathways or barriers to 
access to referrals for genetic testing and follow 
through by parents.  
 
 Further research is needed to understand the exact 
pathways by which some families are referred and 
receive genetic testing while others do not.  
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Physician-patient Communication About Genomic Tumor 
Testing:  Perceptions Of Oncology Providers
A l e x a n d r a  M c C o w n ,  C a i t l i n  G u t h e i l ,  M S ,  H a y l e y  M a n d e v i l l e ,  M P H ,  E r i c  A n d e r s o n ,  P h . D . ,  P a u l  H a n ,  M D ,  M A ,  M P H
C e n t e r  f o r  O u t c o m e s  R e s e a r c h  a n d  E v a l u a t i o n  ( C O R E )  a t  M a i n e  M e d i c a l  C e n t e r  R e s e a r c h  I n s t i t u t e  ( M M C R I )
Background
• Genomic tumor testing (GTT) is a new 
technology and a cornerstone of the 
“precision medicine” movement in cancer 
care.
• GTT uses next-generation genome 
sequencing technology to identify somatic 
variants in tumor cells.
• By identifying somatic variants that predict 
responses to cancer therapies, GTT can help 
tailor therapy to individual patients, making 
them more effective.
• However, GTT also detects many variants of 
uncertain significance, its clinical value is 
currently unproven.
• When using GTT, physicians need to counsel 
patients about both its value and its 
limitations, but the ideal goals and elements 
of physician-patient discussions have not 
been clearly defined. 
• The Jackson Laboratory’s Maine Cancer 
Genomics Initiative (MCGI) is a 5-year state-
wide research project aimed at disseminating 
and implementing GTT in community 
oncology practices throughout the state of 
Maine.
• In April 2018, 76 physicians and clinical staff 
attended an annual 2-day MCGI conference, 
convened by JAX to educate and update 
providers on the progress of the initiative.
• Conference participants were surveyed about 
their beliefs and attitudes regarding GTT.
• Surveys consisted of both multiple-choice and 
open-ended questions, designed to assess 
perceptions of the key goals and elements of 
physician-patient discussions of GTT.
• Multiple-choice question (Key goals)
“What do you think are the three (3) most 
important goals when introducing GTT to a 
patient?” (respondents chose from option list)
• Open-ended question (Key elements)
“Given what you know about  GTT, how would 
you introduce it to a patient? Identify three (3) 
essential things the patient needs to know.”
• Frequencies of multiple-choice responses were 
tabulated.
• Analysis of open-ended items was conducted 
using qualitative methods.
• Software-assisted coding with MAXQDA™
Methods
Goal Options n
Inform patients about benefits and 
limitations of genomic tumor testing
66
Manage patients expectations about 
genomic tumor testing 
56
Facilitate decision making 54
Understand patient preferences for 
genomic tumor testing 
30
Maintain patient hope 9
Encourage patients to undergo genomic 
tumor testing 
3
Share your personal viewpoints on 
genomic tumor testing 
1
Key Content Elements of Discussions
“Given what you know about GTT, how would you introduce it to a patient?” 
Conclusions 
• Cancer care providers identify several 
different goals for physician-patient 
discussions about GTT
• The most commonly prioritized goals 
relate to informed and shared 
decision making, and managing 
patient expectations.
• Providers identify a variety of different 
content elements for physician-patient 
discussions about GTT:  nature of GTT, 
uncertainties about its value for treatment 
decisions, and patient expectations
• Key elements regarding the nature of 
GTT focus mainly on the meaning 
and rationale for GTT, rather than its 
potential harms or disadvantages.
• Key elements regarding uncertainty 
in GTT focus mainly on therapeutic 
options and incomplete evidence.
• Future research directions:
• Replicate and assess the 
generalizability of the findings in a 
larger, more diverse sample.
• Assess patients’ perceptions of the 
goals and ideal content of physician-
patient discussions of GTT.
• Develop and test patient education 
and decision support interventions to 
facilitate informed and shared 
decision making about GTT.
• Develop and test interventions to 
train physicians in facilitating shared 
decision making and managing 
patient expectations about GTT.
Abstract
Genomic tumor testing (GTT) is a potentially 
valuable new technology that can make cancer 
treatment more “precise,” but there are 
substantial uncertainties about its clinical value 
and appropriate use.  Oncology physicians need 
to counsel cancer patients about both the value 
and uncertainties about GTT, but optimal 
strategies remain to be determined. 
This study explored oncology providers’ 
perspectives on the essential content elements 
of physician-patient discussions about GTT.  76 
oncology providers who attended the annual 
meeting of the Jackson Laboratory’s Maine 
Cancer Genomics Initiative (MCGI) were 
surveyed regarding their views about the key 
elements of GTT and goals of communication, 
which were consistent with the ideal of shared 
decision making (SDM).  Study findings will be 
used to design patient education and physician 
training programs to promote SDM in GTT.
Key Goals of Discussions
“What do you think are the three (3) most important 
goals when introducing genomic tumor testing?”
Discuss 
nature of 
GTT
Convey 
uncertainty 
about GTT
Maintain 
expectations 
about GTT
v “Every cancer is unique / This is a way to utilize precision medicine and offer a 
more personalized treatment based on cancer genomics and identifying specific 
genes and mutations associated with patient’s individual cancer” 
v “Testing the cancer genome and not germline/ Looking for an unusual and novel 
alteration in the genome that may give us insight into additional ways to treat 
your cancer” 
v “The chance of finding a practical – treatment is small but if found could 
lead to major benefit” 
v “Emerging technology; some meaning well understood, some not”
v “There may be no information that helps at this time but potential for future 
treatment” 
v “The results may help identify one, none, or several mutations in your tumor / 
we hope the results will help guide future treatment options, however we don’t 
always find mutations that we can take action on- or change the treatment” 
a.mccown207@gmail.com
Participants n
Oncology physicians 17
Registered nurses 14
Genetic counselors 5
Pathologists 5
Other (e.g. practice administrators, genetic 
counselors, other physician specialists) 
35
Total 76
Key Elements of Physician-Patient Discussions
Nature of GTT
(n=201)
Uncertainty about 
GTT 
(n=59)
Patient 
Expectations
(n=24)
GTT Background 
Information 
(n=48) 
Potential 
Outcomes of GTT
(n=25)
Logistics of 
Testing
(n=43) 
Genetics 
& 
Genomics 
(n=21) 
Potential 
Harms
(n=7)
Discovery of 
Germline 
Variants 
(n=11) 
Uncertainty about 
Therapeutic Options 
(n=26) 
Uncertainty from 
Incomplete 
Evidence
(n=10) 
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Flow Cytometric Analysis of Circulating 
Microparticles After Cardiac Arrest
Nathan L. Pinnette1, Mary Weatherbee1, Joanne Dekay1, M.S., Sarah Peterson1, M.D., PhD, Angela Kosta1, B.S., Haifeng Yin1, PhD, Douglas 
Sawyer1,2, M.D., PhD, Michael Robich1,2, M.D., David Seder2, MD, Sergey  Ryzhov1, PhD
1Maine Medical Center Research Institute, Scarborough, ME
2Maine Medical Center, Portland, ME
Cardiac arrest (CA) is an electrical malfunction of the heart that
causes an irregular heartbeat (arrhythmia). Because of this
arrhythmia an insufficient amount of blood is pumped to the vital
organs. CA has a survival rate of only 10 percent and those who
survive suffer from post-cardiac arrest syndrome (PCAS). PCAS
is defined as a condition after resuscitation following a massive
ischemia-reperfusion injury to all organs most notably of but not
limited to the brain. PCAS is characterized by development of
systemic inflammatory response, which contributes to additional
brain tissue damage.
Microparticles are tiny particles in our blood. The two major
ways microparticles are created: 1) cellular activation/stress and
2) cell apoptosis. In addition, immune complexes add to the pool
of circulating microparticles. Microparticles are known to cause
inflammation, coagulation, and effect vascular function.
Since CA is associated with global ischemia/reperfusion-induced
cellular stress and apoptosis, we hypothesized that the number
of circulating microparticles should increase in CA patients.
Study participants: Research was performed in accordance with
study protocols approved by Maine Medical Center Institutional
Review Board, which is accredited by the Association for the
Accreditation of Human Research Protection Programs
(AAHRPP). Post-CA subjects age 18 years or older, admitted to
the ICU after a cardiopulmonary arrest and treated with
Targeted Temperature Management were enrolled after
informed consent of the medicolegal Power of Attorney.
Subjects underwent phlebotomy at 6, 12, 24, 48, 72 and 168
hours after Return of Spontaneous Circulation (ROSC). Control
subjects underwent Coronary Artery Bypass Graft (CABG)
surgery. Inclusion criteria included patients 18 years of age or
older scheduled for open heart surgery supported by
cardiopulmonary bypass (CPB) at Maine Medical Center.
Plasma Samples: Venous blood (10 ml) was collected from
cardiac arrest and control CABG subjects using BD Vacutainer
ACD tubes. Platelet-free plasma was prepared at room
temperature using two-step centrifugation, each at 2,000g for 20
minutes. After preparation plasma was stored at - 800C until
further analysis.
Cerebral Performance Category (CPC): CPC is a neurological
test based on a scale of 1 through 5. 1 being the best and 5
being the worst.
1 - return to normal cerebral function and normal living
2 - cerebral disability but sufficient function for independent
activities of daily living
3 - severe disability, limited cognition, inability to carry out
independent existence
4 – coma
5 - brain death
Flow cytometric analysis: was performed using a MACSQuant®
Analyzer 10 (Miltenyi Biotec, Inc.) and the data were analyzed
with WinList 5.0 software. Trucount and sigma microbeads were
used to set gates and calculate the number of circulating
microparticles.
Data: Data were analyzed with GraphPad Prism 7.0 (GraphPad
Software Inc., San Diego, CA). Comparisons between two
groups were performed using two-tailed unpaired t tests.
Comparisons between several treatment groups were
performed using one-way ANOVA followed by Multiple
comparison tests. A P value < .05 was considered significant.
Figure 1. Flow cytometric gating strategy to calculate the number of circulating
microparticles in platelet-free plasma. Fluorescencein isothiocyanate-labeled (FITC-labeled)
microbeads are used to set gates. Gates are used to remove background noise and record the
percentage of all events that occur in the gate. This diagram shows that all of the microbeads
are removed by the 0.1 micrometer filter.
Figure 2. The number of circulating microparticles in СA subjects at 6 hours is
significantly higher compared at 24 hours and 72 hours after ROSC. Control (CABG, n =
36) patients do not have a significant difference in the number of circulating microparticles
compared to any of the CA subjects (n = 44). Statistical significance was calculated using one-
way ANOVA, p values from Dunn’s multiple comparisons test are indicated.
Figure 3. There is no difference in number of microparticles between CA and control subjects.
Circulating microparticles were measured in platelet-free plasma of CABG subjects (control, n= 36) , survivors
(n=19) and non-survivors (n=22) after CA at different time points after ROSC. Statistical significance was
calculated using one-way ANOVA, p values from Dunn’s multiple comparisons test are indicated.
Figure 4. Good CPC scores have significantly higher numbers of circulating microparticles compared
to undesired CPC scores for CA subjects 48 hours after ROSC. Circulating microparticles were measured
in platelet-free plasma of good and poor CPC scores after CA at different time points after ROSC. Statistical
significance was calculated using t tests, p values from Mann-Whitney test are indicated.
The number of circulating microparticles is not different between CA and control (CABG) patients.
The number of circulating microparticles is characterized by high variability on day two after cardiac arrest with significantly increased 
number of microparticles in CA patients with good CPC scores compared to CA patients with poor CPC scores.
Immunophenotypical analysis should be performed to determine if CA induces changes in origin of circulating microparticles.
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Sympathetic and sensory innervation of bone 
modulates remodeling
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Research on the relationship of skeletal physiology and the nervous system has exploded in 
the last 25 years2. Studies of β-adrenergic ligands and bone density have well established an 
inverse relationship between sympathetic nervous output and bone metabolism (Figure 1)5. 
Recently, the role of sensory nerves have also been considered to the story (Figure 2) . The 
precise mechanisms of neuro-osteogenic crosstalk remain obscured. A better understanding 
innervation with respect to bone remodeling will inform treatment of bone  pathologies and 
disease4. We use immunohistochemical staining techniques to elucidate the phenotypes, 
distribution and organization of nerve fibers in bone. Semiconductor nanocrystals (quantum 
dots) have more desirable optical qualities than organic dyes and fluorophores6, and will be 
used to overcome the inherent difficulty in confocal imaging of bone. 
Abstract
Introduction
• Fixed, frozen tissue sections of long bones and L5 vertebrae from transgenic mice 
expressing gfp driven by sequence under trpm8 promoter.
• IHC performed to visualize neural markers and trpm8 with fluorescent markers.
• Quantum dots (Figure 4) conjugated to secondary antibodies (Figure 3) in lieu of organic 
fluorophores; for signal amplification  to compensate for high auto fluorescence and as proof 
of principle for future studies.
• Images (Figures 6,7) from confocal microscope analyzed with Autoquant and Imaris
software.
Methods and Materials Discussion
• Multiplex imaging (Figure 9) of multiple neural markers and receptors (TH, CGRP, TRPM8, ) to show 
colocalization, giving clues to communication mechanisms.
• Quantitative comparison of neural organization and density between long bones and vertebrae.
• Study changes in neural density from neuropathy in mouse BTBR Ob/Ob diabetes model.
Future Directions
Bone remodeling is a continuous, ubiquitous process. Sympathetic nervous output  shifts 
this equilibrium towards increased resorption and decreased bone formation. The myriad of 
factors by which the nervous system  interacts with the skeleton (hormones, peptides, 
neurotransmitters [serotonin], etc.) comprise a somewhat “black box” type system. There is 
observable input and output, but incomplete understanding of the internal workings . The use of 
immunofluorescent neural markers seems promising in shedding light on this system. However, 
immunohistochemistry (IHC) and confocal imaging of bone present difficulties. The requisite  
fixation time and decalcification reduces antigenicity. This diminishes  signal strength,  which in  
addition to the high auto fluorescence  and low neuron density of bone has lead to few labs 
reliably able to perform these techniques routinely1. 
An efficient, reproducible technique for visualizing and quantifying the  differential 
innervation of bones will be quintessential in understanding the complex network between bone 
and brain3. 
Results
Figure 1. Sympathetic control of bone response4. 
Figure 7. Inconclusive staining for sympathetic 
innervation in growth plate of Tibia/Fibula. Tyrosine 
hydroxylase (TH) is an enzyme involved in the 
production of catecholamines and localizes 
sympathetic nerve fibers . Maximum intensity 
projection of confocal 10 μm z-stack, 20x objective.
Acknowlegdements: This research is supported by NIH/NIAMS KO1AR067858 to KJM;
NIH/NIGMS P20GMS, P20GM12301 to KJM; NIH/NIGMS P30GM106391, P30GM103392,
P20GM121301 U54GM115516 to Maine Medical Center.
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motylk@mmc.org
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(Pan neuronal marker)
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Figure 6. Strong evidence supporting sensory 
innervation along periosteum of femur. Tropomyosin 
Receptor Kinase A (Trka) is a NGF receptor and 
localizes sensory nerve fibers. Confocal image with 
20x objective, 405 nm excitation .
Figure 8. 3d Reconstruction (Autoquant) 
of Figure 7 with potential neurons 
traced with Imaris “filament” algorithm
Dapi/Trpm8
Unfortunately, we have not yet optimized technique enough to isolate meaningful signal from 
background, although positive staining has generally been in the reasonable location but lacks any 
“nerve like” morphological characteristics. Must titrate to detergent concentration, antibody 
type/dilution/incubation times to optimize staining. Rigorous negative controls and positive controls 
(with dorsal root ganglia) will be required to confirm specificity of assay results. Further investigation of 
trpm8 localization in bone needed to reveal any potential role in mediating bone homeostasis.
Figure 2. Afferent sensory nerves relay local 
mechanical conditions to the brain
Figure 3. Indirect Immunofluorescence with Quantum Dot
Antigen of interest
Figure 4.
100 μm
Figure 5. Flow chart of standard skeletal 
preparation with changes in orange
Figure 9. Design for single UV 
excitation multiplex assay for 
variety of neurochemical 
phenotypes
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Differential Gene Expression in Adipose Tissue 
of M. musculus Fed a High Fat Diet
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Perivascular adipose tissue (PVAT) surrounds the systemic 
vasculature of the body where it acts as mechanical support and 
secretes cytokines that affect the profile of the underlying vessel. 
The direct proximity of PVAT to the adventitia of blood vessels 
and its secretion of vasoactive factors that regulate vascular tone 
make it especially relevant to the study of cardiovascular disease. 
In healthy individuals, PVAT produces anti-inflammatory and 
anticontractile cytokines that promote vascular health. In 
cardiovascular disease and obesity, dysfunctional PVAT reduces 
vascularization and increases inflammatory response and 
vasoconstriction. Currently, there are no known molecular 
markers unique to PVAT, which limits investigation into possible 
treatments to encourage a healthy PVAT profile. The discovery of 
PVAT specific markers would allow for the development of novel 
tools to study this depot, and could lead to clinically relevant 
interventions to improve vascular function. 
Fig. 1. Differential phenotype of 
perivascular adipose tissue in healthy 
individuals vs. cardiovascular disease.  
Perivascular adipose tissue and vascular health
High Fat Diet 
Protein Signatures
Regular Diet High Fat Diet
PVAT
gWAT
BAT
Control Diet
Protein Signatures
Proteomic data highlighted differential expression 
of proteins in perivascular adipose tissue (PVAT) of 
mice fed a high fat diet (HFD) versus those fed a 
control diet (CD). Twelve candidate genes with 
significantly different protein levels were identified 
as potential protein markers unique to perivascular 
adipose tissue. 
Candidates were divided into two categories: those 
proteins upregulated in gonadal white adipose 
tissue (gWAT), brown adipose tissue (BAT), and 
PVAT in mice fed a high fat diet; and proteins 
upregulated in BAT and PVAT and downregulated in 
gWAT of mice fed a high fat diet. Transcriptome 
verification via qRT-PCR of the first category was 
performed.
Gene candidate selection
Fig. 2. Proteomic assay performed on tissues 
collected from M. musculus fed a HFD or CD 
for 12 weeks. 
Transcript abundance of candidate genes in BAT, IWAT, gWAT
Table 1. Candidate proteins displaying differential abundance from protein mass spectrometry of adipose tissues. Tissues were collected from mice 
fed a high fat diet vs. control diet for twelve weeks.
Conclusion and future directions
Gene Name gWAT CD gWAT HFD BAT CD BAT HFD PVAT CD PVAT HFD
S27A2 Very long-chain acyl-CoA synthetase 1,041 6,294 19,618 33,436 2,436 16,485
HMCS2 Hydroxymethylglutaryl-CoA synthase 6,771 50,776 2,399 6,749 2,115 11,594
PLIN2 Perilipin-2 16,034 219,927 19,137 33,800 14,437 41,056
ANXA1 Annexin A1 1,311,051 2,012,223 84,678 138,520 49,419 132,267
HSDL2 Hydroxysteroid dehydrogenase-like protein 2 142,657 156,959 317,538 475,215 136,610 309,144
TAGL2 Transgelin-2 773,866 1,083,330 198,420 293,259 123,726 196,127
TissueMethodology
• Mapping of genomic DNA and mRNA and primer design for candidate 
genes
• Stringent validation of primers in multiple tissues
• Mechanical homogenization of experimental tissues
• RNA isolation: Tissue lysis and affinity chromatography purification
• qRT-PCR amplification and analysis of relative transcript abundance
RNA
qRT-PCR
Analysis
Proteins enriched in M. musculus adipose tissues on HFD
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Fig 3. Differential RNA abundance in adipose depots on HFD. qRT-PCR results show differential RNA abundance in adipose depots 
on HFD. Y-axis shows relative percent difference of HFD vs. CD as calculated using 2-∆∆Ct. Ppia (Cyclophilin A) was used as the 
reference gene. qRT-PCR reactions contained 10ng of cDNA and 300nM primer concentration. Cycle: 95˚C, 3 min; 95˚C 15 seconds, 
60˚C 30 seconds x 40 cycles. n=2. 
The transcriptome did not directly corroborate the proteomic data, with the exception of Anxa1 and Tagl2. Moving forward, this 
experiment will be extended to include PVAT from CD and HFD mice, and the data from all adipose depots will be validated at the 
protein level via western blot. Candidate genes from the second category identified in the proteomic assay—proteins with higher 
expression in PVAT and BAT but no change or a decrease in gWAT—will be evaluated along the same course as outlined here. 
Genes determined to have differential expression in PVAT at the protein and transcript level, with be further investigated as potential 
PVAT markers.
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Background Results
Materials and Methods
Transfer Patient Characteristics
• Interfacility transfers are common in rural states where few hospitals 
admit children. Pediatric hospitalizations admitted via transfer cost 
$19.5 billion in 2012.1
• As many as 25% of  transferred pediatric patients are discharged 
within 12 hours of  arrival and do not have any further work-up.2
• Understanding what pre-transfer factors are associated with shorter 
LOS may help avoid unnecessary transfers.
• All  pediatric direct admissions from referring hospitals and urgent 
care centers to the Maine Medical Center IPUs and PICU, as well as 
all transfers to the ED for evaluation by the pediatric hospitalist 
service during the months of  August 2016-January 2017 were 
enrolled.
• The patient’s electronic medical record and/or HealthInfoNet data 
were manually reviewed. Data were entered into a secure database 
(REDCap™).
• Medical Complexity was assigned using a standardized method.3
• Vital signs were determined to be abnormal or normal using the 
Pediatric Advanced Life Support (PALS) algorithm.4
• Statistical analyses were performed using SPSSTM statistical software, 
version 25 (IBM SPSS Inc, Armonk, NY). 
Pediatric Interfacility Transfers – Association of Pre-transfer Vital Signs 
with Length of Stay at a Tertiary Care Center
Sarah Bunting BA, Leah Mallory MD, Logan Murray MD
Maine Medical Center, Department of Pediatrics, Portland Maine
• Further research is necessary to increase the generalizability of  this 
study, with the addition of  other hospitals.
• Create a guideline where accepting pediatric providers obtain all five vital 
signs before accepting the patient. This could allow for the study of  
another objective measure of  decompensation such as Bedside Pediatric 
Early Warning System (BPEWS) with LOS. 
Objectives
Special thanks to Wendy Y. Craig, PhD at the Maine Medical Center Research 
Institute for her invaluable assistance with statistical analysis of  data which was 
supported in part by the Northern New England Clinical and Translational Research 
grant U54GM115516. 
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Next Steps
Conclusions
• Many patients were discharged quickly after transfer; 5.9% in <6 hours; 
11.9% in <12 hours; and 30.9% in <24 hours. 
• Most vital signs were reliably obtained (HR for 93.6% of  patients; RR, 
90.7%; temperature, 87.3%; spO2, 92.4%). BP was an exception at 
47.9%.
• Patients with abnormal RRs before transfer have significantly longer 
LOS than patients with normal RRs (61 v. 38 hours, p= 0.017). The 
same finding was apparent for BP (57 v. 31 hours, p= 0.035). 
• Abnormal HR, temperature, and spO2 alone did not correlate with 
LOS.
• When controlling for temperature, there was no significant difference in 
LOS for patients with pre-transfer abnormal HRs.
• Younger patients were less likely to have a recorded BP (p=<0.001), 
with a 10.75 year gap in median ages.
• Apparent trend toward abnormal RR being associated with unexpected 
transfer to PICU in 24 hours. Six out of  8 unexpected transfers had 
abnormal RRs.
• Additionally, median LOS increased with medical complexity (p= 0.028).
1.) Determine whether an association exists between abnormality of  
pre-transfer vital signs and LOS.
2.) Identify pre-transfer vital signs associated with morbidity, such as 
unexpected transfer within 24 hours from the inpatient units (IPUs) to 
the PICU.
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Variable Median [range], or n (%)
n 236
Age (months) 67.5 [0-225]
Male sex 122 (51.7)
Medical complexity: 
Non-chronic
Non-complex chronic
Complex chronic
118 (50.0)
80 (33.9)
38 (16.1)
Admission type:
Direct to IPUs
Direct to PICU
Not direct
78 (33.1)
51 (21.6)
107 (45.3)
Hospitalist Service Involved 185 (78.4)
LOS (hours) 42.5 [2.6-1392]
Early Discharge/Unexpected Transfer:
D/C from MMC ED
Transfer from IPUs to PICU in 24h
Transfer to other hospital in 24h
13 (5.5)
10 (4.2)
1 (0.4)
Pre-transfer Vital Signs and Median LOS
1 Mann-Whitney U test
• This study demonstrates a significant association between both 
abnormal pre-transfer RR and BP with longer LOS in pediatric patients 
at a tertiary care facility.
• It supports no significant correlation between abnormal HR, 
temperature, and spO2 with LOS. 
• These results may better help both referring and accepting providers 
predict the course of  patient care after transfer.
p= 0.0171 p= 0.0351
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3T3-L1 model of adipogenesis and effects of methionine restriction
Sharon Jordan, Emily Cooper, Lucy Liaw PhD
Maine Medical Center Research Institute, Scarborough, Maine.
Sharonajordan@smccme.edu
Abstract
Materials and Methods
Healthy adipose tissue has an important role as an endocrine organ that affects whole body health. 
One example is the secretion of adiponectin, a hormone that aids in regulating glucose levels and 
breakdown of fatty acid. There are several types of adipose tissue. Perivascular adipose tissue 
(PVAT) surrounds most of the large blood vessels including the aorta. PVAT has thermogenic and 
vaso-protective properties. In obesity PVAT exhibits structural and functional changes. Unhealthy 
adipose tissue can become inflamed and inhibit the beneficial adipokines. Methionine reduction 
has shown to increase health span in mouse models. The methionine restricted mice continued to 
maintain healthy weight and improved glucose metabolism. To understand how methionine 
restriction alters adipose tissues, we initially used the 3T3-L1 cell line. 3T3-L1 is a fibroblastic line 
that can be differentiated into adipocytes and will be a useful model for altering methionine during 
adipogenesis in vitro. We used an adipogenic cocktail to induce these cells along the path to mature 
adipocytes. Oil Red O staining was used to view lipid accumulation and we performed initial 
studies with different concentrations of methionine in the medium. Our next aim is to test if the D-
isomer of methionine is metabolized differently than the L-isomer. This is important to develop an 
accurate optimal methionine concentration. Having a cell model will be beneficial for future study 
into activities of methionine restriction in adipocytes. In addition, it will set the stage for continued 
studies with primary cells derived from PVAT.
Culture and Differentiation 3T3-L1 model of adipogenesis
The 3T3-L1 cell line was used to study adipogenesis in vitro. The 3T3-L1 line has a fibroblast-like 
morphology when grown under standard culture conditions. (see fig.1) Media consists DMEM/F12 with 
10% FBS. For differentiation, 3T3-L1 cells were grown to 75-80% confluence and switched to 
adipogenesis induction medium. After 72 hours induction cells were switched to maintenance medium. 
The maintenance medium was changed every three days, leaving 25% medium in the plate and adding 
75% fresh maintenance medium. Cells are maintained in maintenance medium for 8 to 10 before 
collection?
Methionine Concentration Variations in Media
To make medium with varying concentrations of methionine, DMEM/F12 and DMEM high glucose with 
no methionine was ordered (Gibco). Dialyzed FBS was used to ensure no added methionine was present. 
Induction and maintenance medium was made using methionine the methionine free components. 
Methionine free medium is mixed with standard medium to obtain desired concentrations.
Analysis of Adipocyte Differentiation
To determine the level of lipid accumulation oil red o (ORO) staining was used. The ORO stock solution 
is 0.35g ORO per 100ml 100% isopropanol. The working solution is 3 parts ORO stock 2 parts diH2O 
(0.05µg/ml). Cells were fixed in 10% neutral buffered formalin. Formalin was added slowly to the side of 
the well and aspirated off after one hour. Cells were rinsed with diH2O. After aspirating off the diH2O, 
60% isopropanol was added to the well and the plate rotated to cover the cells.. The isopropanol was 
aspirated, and the ORO working solution added and incubated for 10 minutes on a rocking platform. The 
ORO solution was removed, and cells rinsed with diH2O twice followed by 3x10 minute diH2O washes 
on a rocking platform. Images were taken of the cells to document the ORO staining. The ORO stain was 
eluted with 100% isopropanol, and the absorbance of the solution was measured at 490 nm. 
Results
3T3-L1 model of adipocyte differentiation
Effects of methionine modification on adipocyte cell number and 
differentiation
Figure 2. Effects of methionine modification on adipocyte cell number and differentiation
a.) Absorbance of crystal violet dye was measured to estimate the amount of cells that survived under each methionine 
condition. b.) Oil red O was used to stain the lipid. Amount of Accumulated Oil Rd O was normalized to amount of CV in 
corresponding cells.  
Conclusions and Discussion
Acknowledgements
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supportWe confirmed that 3T3-L1 cells have the capacity to differentiate  into 
adipocytes based on oil red O staining of neutral lipids in the differentiated 
cells. Using these cells as a model to test the effects of methionine restriction 
on the adipogenic capacity of the cells, we found that cells containing a 
racemic mixture of 0.0184mM methionine (D and L isomers) had enhanced 
survival and reduced lipid accumulation as compared to other tested 
concentrations of methionine. These results suggest that methionine is 
content is an important regulator of adipogenesis. This data shows that in the 
future experiments it will be important to measure not only lipid 
accumulation but cell growth and survival rate. 
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Figure 1. Adipogenic differentiation of 3T3-L1 cells 
a) 3T3-L1 cells before differentiation. b)  3T3-L1 cells after successful differentiation and lipid stained with oil red O.                                         
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Characterizing the pluripotency of human thoracic 
perivascular adipose tissue progenitor cells
S. Spencer Scott, Joshua Boucher, Xuehui Yang, Lucy Liaw
This work was possible thanks to the generosity of Beth DeTine and the Paul Gray Scholarship.
Perivascular adipose tissue, or PVAT, is a specialized form of 
fat tissue that encompasses major vasculature in the body. 
While this tissue was once thought to be primarily structural in 
nature, PVAT is now understood to play a significant role in 
regulating vascular health. In metabolically healthy 
individuals, PVAT both promotes vasodilation and inhibits
inflammation. In metabolically unhealthy individuals, as in 
conditions of obesity, PVAT expands through a process called 
hypertrophy and loses its protective functions, exacerbating the
risk of cardiovascular disease. Since 2016, the Liaw lab at the 
MMCRI’s Center for Molecular Medicine has made the study of 
perivascular adipose tissue a primary focus of its work.
Through a collaboration with cardiac surgery at Maine Medical Center, the
Liaw lab has been able to receive human PVAT specimens collected 
incidentally during coronary artery bypass graft (CABG) procedures. To
accommodate grafting the new vasculature to the aorta, the local PVAT tissue 
must be cleared away. These samples are then provided to MMCRI for 
multiple avenues of study, including explanation of primary cells.
The Liaw lab’s Joshua Boucher, PhD, has been able to explant progenitor cells from these human PVAT samples and 
successfully induce them to differentiate toward an adipogenic lineage. The success of differentiation was assessed by 
staining for neutral lipid accumulation with Oil Red O as well as probing for expression of genes specific to mature 
adipocytes, such as PPARγ and PLIN1 or perilipin 1. However, a major question still remains: How committed are these 
progenitor cells yielded by explantation of human thoracic PVAT to an adipogenic lineage? This project seeks to begin to 
illuminate the pluripotency of these primary cells by examining their ability to differentiate toward other cell lineages, 
specifically osteogenic and chondrogenic.
While burgeoning research on perivascular adipose tissue begins to illuminate the complex relationship between these unique 
fat deposits and the blood vessels to which they are localized, broad cellular and molecular characterizations of PVAT are still
sparse. Furthermore, work with PVAT specimens collected from human donors remains limited in this exciting area of vascular 
research. At the Liaw lab, thanks to a collaboration with surgery at Maine Medical Center, human thoracic PVAT samples have 
been collected incidentally during cardiac surgical procedures and primary human PVAT cells have been explanted from the 
collected tissue. This project attempts to explore the nature of these explanted cells, presumed to be the progenitor cells that
reside among PVAT and replenish the tissue in periods of regeneration or growth. A major question regarding these cells is the 
extent of their pluripotency. To probe this question, this project attempted to induce the PVAT primary cells toward an 
adipogenic, osteogenic, and chondrogenic lineage in three concurrent induction assays. The cells were cultured for 14 days in 
their respective induction media and then fixed in formalin. Subsequently, the cells were stained using Oil Red O to assess the 
success of adipogenic induction, Alizarin Red for osteogenic induction, and Masson’s trichrome for chondrogenic induction. This 
preliminary work seems to suggest that these human primary PVAT cells are capable of adipogenic and chondrogenic 
differentiation, but incapable of induction toward an osteogenic lineage.
Background
Fig. 1. Following 14 days of induction, the explanted 
human thoracic PVAT cells displayed a robust ability to 
differentiate toward an adipogenic lineage as assessed by 
the accumulation of neutral lipids, stained here with Oil 
Red O. In image 1c, the non-induced condition is shown at 
14 days with virtually no apparent neutral lipid 
accumulation.
40X 1b
20X 1a
1c20X
Adipogenic
Bone Marrow MSC
20X 2a
Abstract
Fig. 2. In the osteogenic induction assay human bone marrow mesenchymal stem cells were cultured alongside human thoracic 
PVAT cells, both in osteogenic differentiation medium. At the end of 14 days of induction, Alizarin Red was used to stain for free 
calcium and calcium compounds, evidence of mineralization and osteogenic induction. Staining of the bone marrow MSCs showed 
a markedly larger amount of mineralization than the PVAT cells, in which the staining was sparse. This suggests that the human 
thoracic PVAT cells were not able to differentiate toward an osteogenic lineage by the 14 day time point, unlike the MSCs.
PVAT
20X 2b
Osteogenic
Chondrogenic
Fig. 3. In the chondrogenic induction assay, shown in these images, human thoracic PVAT cells 
were cultured using a “micromass” technique which allows for the growth of a pellet of roughly 
107 cells in the center of a culture dish. These cells were cultured in chondrogenic differentiation 
media for 14 days and then the cell pellet was embedded in paraffin and stained using Masson’s 
trichrome, of which the blue stains for collagen. In multiple pellets of human thoracic PVAT cells, 
the structure was positive for collagen, suggesting successful induction toward a chondrogenic 
lineage.
PVAT
10X
PVAT
3a 10X
PVAT
102X
PVAT
3b 3c
Non-induced
PVAT
Human PVAT-APC differentiate to adipocytes in vitro a) Oil red O (ORO) staining of lipids in non-induced (top) and 
induced (bottom) at day 7. b) Immunoblot for the indicated proteins of non-induced and induced PVAT-APC for 7 and 14 
days. 
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Neoadjuvant Therapy versus Upfront Surgery for Resectable Pancreatic Cancer 
using the NCDB database: A Decision Analysis 
William Olsen BA, Roberto Vidri MD, David Clark MD, Timothy Fitzgerald MD
Maine Medical Center, Department of Surgery, Portland Maine
• Pancreatic adenocarcinoma (PAC) is the third leading cause of cancer-
related death in the United States and an estimated 44,330 people will die 
from PAC in 20181.
• The only curative treatment at this time is resection, yet only 10-20% of 
patients are considered clinically resectable at the time of presentation2.
• Currently there are no prospective clinical trials that have shown benefit of 
neoadjuvant therapy (chemotherapy first) compared to upfront surgery in 
resectable PAC patients, and there are only retrospective single-institution 
studies3.
• Studies have have shown that receiving chemotherapy at some point is 
advantageous compared to just surgery, but the sequence is debated4. 
• Compare the overall survival rates of patients with stage I and II 
resectable pancreatic adenocarcinoma who receive neoadjuvant 
chemotherapy and surgery versus patients who receive upfront surgery 
and adjuvant chemotherapy. 
• Use a decision analysis to compare neoadjuvant therapy and upfront 
surgery, including rates of dropout from each group.
• Identify therapeutic and pathologic characteristics of neoadjuvant and 
upfront surgery patients associated with improved survival. 
• Retrospective cohort study utilizing the NCDB database from 2004-2015 
comparing patients who received neoadjuvant therapy and surgery versus 
patients who received upfront surgery and adjuvant therapy.
• 32,498 patients were selected by the following characteristics:
• Invasive behavior of the tumor
• Histology of Carcinoma NOS (8010), Adenocarcinoma (8140), and 
Ductal carcinoma (8500)
• TNM Stage I and II
• T1N0M0, T1N1M0, T1NXM0, T2N0M0, T2N1M0, T2NXM0
• Patients undergoing palliative care were excluded
• Patients who refused surgery were excluded
• Descriptive statistics were used analyze the data
• Prospective, randomized controlled trials comparing neoadjuvant 
therapy against an upfront surgical approach are needed to 
better answer this question.
• Though chemotherapy before surgery has a slightly higher 5 year 
survival rate when compared to the surgery first group, the dropout rate 
is such that 72.1% of patients never make it to surgery, thus never 
giving them a chance for a cure.
• Using the decision tree, there is a 13.1%, 5 year survival benefit to 
receiving surgery first.
• Using Cox Regression analysis, patients were more likely to receive 
surgery if they had private insurance, were at an academic center, and                                      
lived in a metropolitan area. 
• Patients were less likely to receive surgery first, if they were older than 
65, male, had multiple comorbidities, had a poor tumor grade, had a 
tumor of the pancreatic head or neck.
1. Cronin KA, Lake AJ, Scott S, et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 
2018;124(13):2785-2800.
2. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining 
outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91(5):586-594.
3. de Geus SW, Evans DB, Bliss LA, et al. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A 
Markov decision analysis. Eur J Surg Oncol. 2016;42(10):1552-1560.
4. Epelboym I, Zenati MS, Hamad A, et al. Analysis of Perioperative Chemotherapy in Resected Pancreatic Cancer: Identifying the 
Number and Sequence of Chemotherapy Cycles Needed to Optimize Survival. Ann Surg Oncol. 2017;24(9):2744-2751.
Variable HR (95% CI) P value
Age, 65-79 1.15 (1.09-1.21) <0.0001
Age, 90-99 1.62 (1.58-1.77) <0.0001
Male 1.05 (1.01-1.08) 0.004
White 1.02 (0.97-1.07) 0.439
Medicare 1.02 (0.96-1.08) 0.551
Private insurance 0.88 (0.83-0.93) <0.0001
Academic center 0.79 (0.77-0.82) <0.0001
Metropolitan area 0.92 (0.88-0.95) <0.0001
Comorbidities 1.15 (1.11-1.18) <0.0001
Poor tumor grade 1.26 (1.21-1.31) <0.0001
Head/Neck Tumor 1.09 (1.06-1.14) <0.0001
Start with Surgery 0.48 (0.46-0.49) <0.0001
P value:
<0.0001
P value:
0.1958
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INFLUENCE OF LYSOSOMAL ACID LIPASE ON OSTEOBLAST 
DIFFERENTIATION AND FUNCTION 
Talia Staiger¹, Elizabeth Rendina-Ruedy1, Ron C. Helderman1, Liv Palma1, and Clifford J. Rosen1 
1Maine Medical Center Research Institute, Scarborough, ME, 04074 
 
REFERENCES 
●  Lysosomal acid lipase (LAL) is an enzyme in the lysosome that breaks down 
cholesteryl esters (CE) and triacylglycerides (TAGs).¹ 
●  In humans, an LAL deficiency presents itself in two diseases: 
○  Wolman Disease -, infants experience severe hepatosplenomegaly and 
malabsorption and usually die before one year of age  
○  Cholesteryl ester storage disease - later onset and milder phenotype, resulting in 
CE  storage in visceral tissues, hepatosplenomegaly, and hypercholesterolemia.¹ 
●  LAL knockout  (KO) mice have increased TAG  
and CE storage in various tissues ², as well as  
defective brown adipose tissue, leading to  
hypothermia at room temperature.³   
 
●  Recently, our lab has demonstrated  
 LAL KO mice also have decreased  
 bone volume/ total volume (BV/TV)  
 in the distal femur metaphysis. 
INTRODUCTION 
HYPOTHESIS AND EXPECTED OUTCOMES 
METHODS 
CONCLUSIONS & SUMMARY FIGURE 2.  10X IMAGES OF BMSCS FROM 
FIGURE 1A ON DAY 5 
●  We hypothesized that LAL supports osteoblast differentiation. 
●  It was expected that higher doses of Lalistat, an LAL inhibiting drug, would slow the 
differentiation of osteoblasts and result in less alkaline phosphatase (ALP) staining. 
ACKNOWLEDGEMENTS 
FIGURE 1.  ALKALINE PHOSPHATASE STAINING OF BMSCS  AFTER 7 DAY LALISTAT TREATMENT 
●  ALP stains showed mixed results amongst the three plates, making the 
results inconclusive even though the photographs showed less confluence 
in the Lalistat-treated wells. 
●  This project taught me the techniques of bone marrow harvesting, cell 
culture, osteoblast differentiation and ALP staining.  Additionally, I was 
exposed to genotyping/ PCR, Cre LoxP models, Seahorse XF96 technology, 
and Confocal Microscopy. 
a) A well from the  (0 uM) control 
group of bone marrow stromal cells  
a) This plate, stained at 7 days, shows increased amounts of 
staining in the control group compared to the 100 µM group. 
(1)  Du, H. (1998). Targeted disruption of the mouse lysosomal acid lipase gene: long term survival with massive cholesteryl 
ester and triglyceride storage. Human Molecular Genetics, Vol. 7. 
(2) Du, H. (2001). Lysosomal acid lipase deficient mice: depletion of white and brown fat, severe hepatosplenomegaly, and 
shortened life span. Journal of Lipid Research, Vol. 42. 
(3) Duta-Mare, M. (2018). Lysosomal acid lipase regulates fatty acid channeling in brown adipose tissue to maintain 
thermogenesis. BBA - Molecular and Cell Biology of Lipids. 
 
Adapted from Hong Du, Journal of Lipid Research, 2001 
This internship was supported by the Summer Student Research Program at Maine Medical Center Research Institute.  
I would also like to acknowledge all of the members of the Rosen lab, Liz Bergst, Drs. Lucy Liaw and Rob Koza. 
RESULTS 
Bone Marrow Stromal (BMSC) Cell Culture 
●  C57BL/6 mice were sacrificed and their femurs, tibias, and iliac 
crests were obtained. Their bone epiphyses were cut off to 
remove the bone marrow through centrifugation with minimal 
medium. The bone marrow pellets were resuspended, 
distributed into flasks with 25 mL alpha MEM complete 
medium, and incubated for 48 hours.  
●  The media and non-adherent cells were aspirated off and the 
adherent cells (BMSC) were treated with 3 mL of trypsin for 
three minutes before 20 mL alpha MEM complete  medium was 
added. The cells were counted and plated at a concentration of 
5.0 x 10 ⁵ cells per well in three 12-well plates.  
Lalistat Treatment 
●  After 48 hours, the alpha MEM complete medium was replaced with 
osteogenic medium containing  50 µg/mL ascorbic acid and 5 mM β-
glycerolphosphate. The cells received this differentiation medium for 
seven days.  
●  Throughout the differentiation, cells received various doses of Lalistat 
at either 0µM (Control), 25µM, 50µM, or 100µM. This treatment also 
lasted for seven days. 
●  At the end of the experiment (day 7) cells were stained for alkaline 
phosphatase (ALP), an osteoblast marker. 
 
 
Nucleus 
Lysosome 
Free cholesterol 
LDL receptor 
LDL  
(CE, TAG) 
LAL 
LDL receptor 
Femur 
Tibia 
Iliac Crest 
ALP stain 
b) This plate, stained at 7 days, shows slightly increased 
staining in the 100 µM group compared to control. 
c) This plate, with cells grown during a different week 
than the other plates, shows equal amounts of 
staining across the wells, and more staining compared 
to the first two plates at 7 days. 
♂WT ♂KO 
b) A well from the 100 µM lalitstat 
group of bone marrow stromal cells 
Nucleus 
Lipid Droplet 
Lysosome 
“Normal” LAL LAL Deficiency 
Lipid Droplet 
SCHEMATIC DEPICTING LAL’S ROLE 
BMSCs 
Adherent  
BMSCs 
Osteoblast Diff 
Lalistat 
(7 days) 
Harvest bone marrow Isolate BMSCs from 
total Bone Marrow 
Plate BMSCs Osteoblast Differentiation 
+/- Lalistat Treatment 
Unpublished data. 
0 25 50 100 
Free fatty acids  
LDL  
(CE, TAG) 
µM 0 25 50 100 µM 0 25 50 100 µM 
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Methods
Predicting Neurological Outcomes Using Pupillometry During Targeted Temperature Management After A Cardiac Arrest
Tyler R. Nussinow,  Mary E. Sawyer, Dave Seder MD, Philip Stone DO, Richard R. Riker MD
Maine Medical Center, Neurocritical Care, Maine Medical Center Research Institute
*A pupilometer is a device used to objectively measure pupil size and reactivity 
to light – a pupil’s reactivity is thought to be directly correlated with brain 
activity.1
*When a person has a cardiac arrest (CA), significant brain damage can result 
due to lack of oxygen to the brain. Targeted temperature management 
(TTM) has been demonstrated to reduce the amount of brain damage that 
occurs in these patients.3
*The goal of this study was to examine data from the pupillometer (specifically 
Neurological Pupil Index (NPi), percent constriction, constriction velocity, and 
pupil size) and compare the values to suggested thresholds1,2 in order to 
predict a person’s neurological outcome. We did this by looking at three time 
intervals: 6 hours after return of spontaneous circulation (ROSC), 24 hours 
after ROSC, and ever. 
*Our hypothesis was that constriction velocity would be a more accurate 
predictor of neurological outcome than NPi and size. 
Acknowledgements
Introduction
 Constriction velocity was an accurate predictor of poor neurological outcome.
 Constriction velocity <0.54mm/sec within 6 hours after ROSC associated with poor 
outcome.
 Constriction velocity <0.32mm/sec 6+ hours after ROSC associated with poor 
outcome.
 NPi value <3 confirmed as an accurate predictor of poor neurological outcome.1.
 Percent constriction <13% confirmed as an accurate predictor of poor neurological outcome.2
 Pupil size confirmed as not an accurate predictor of poor neurological outcome.
CPC 5: Brain death: apnea, areflexia, EEG silence, etc.
Supported by a grant from Maine Medical Center Research Institute Summer Student Research Program
References
Abstract
A pupil’s reactivity to light during targeted temperature management (TTM) after 
a cardiac arrest can help predict the neurological outcome of a patient.1 This 
was investigated by examining pupilometer data from patients admitted to Maine 
Medical Center from August 2017 - July 2018. Neurological Pupil Index (NPi), 
percent constriction and pupil size were compared to previously-established 
thresholds1,2, while this is the first study, to our knowledge, to establish a 
threshold for constriction velocity (via ROC curve). This data was conducted in 
order to find trends consistent with good/poor neurological outcomes in patients 
who suffer from cardiac arrests. A NeurOptics NPi-200 pupillometer was used by 
nurses every few hours (no specific time requirement) both during and after TTM 
in order to get objective pupil exams. Comparison of pupilometer data was done 
by using patient’s worst scoring eye (in each respective category) between 
Good or Poor outcomes and statistically analyzed by using Mann-Whitney, Chi-
Squared, and Fisher Exact tests. This study supports that NPi (=0 and/or <3), 
percent constriction (<13%), and constriction velocity (<0.54mm/sec and <0.32 
mm/sec) at different time periods (<6 hours after ROSC, <24 hours after ROSC, 
or ever) are good predictors in neurological outcomes of patients after a cardiac 
arrest. 
CPC 1: Good cerebral performance: conscious, alert, able to 
work, might have mild neurologic or psychologic deficit
https://neuroptics.com/npi-200-pupillometer/
GOOD POOR
Results
Conclusions
1) Shoyombo et al. Understanding the Relationship Between the Neurological Pupil Index 
and Constriction Velocity Values. Scientific Reports. 2018:8(6992):1-6. 
2) Solari et al. Early Prediction of Coma Recovery after Cardiac Arrest with Blinded 
Pupillometry. American Neurological Association. 2017:0(0):1-7. 
3) Seder et al. The Evolving Paradigm of Individualized Postresuscitation Care After Cardiac 
Arrest. American Journal of Critical Care. 2016:25(6):556-564.
ROC Curves NPi, CV, %C at 6 Hours
N=1  N=15  N=24  N=8     
Next Steps
*Npi=0: 0 of 7 (0%) Good Outcome (n=7; p=0.0934)
*0<Npi<3: 2 of 12 (17%) Good Outcome (n=12; 
p=0.3219)
*Percent Constriction Bilaterally <13%: 8 of 38 (17%) 
Good Outcome (n=46; p=0.0003)
*Size >5mm: 5 of 16 (24%) Good Outcome (n=21; 
p=0.8415)
 Compile data from previous years in order to more accurately be able to demonstrate pupilometer data 
significance  in predicting patient outcomes.
ROC Curve CV at 6 Hours
N=5  N=11  N=32  N=9     N=6  N=11  N=35  N=7     
26
Journal of Maine Medical Center, Vol. 1 [2019], Iss. 1, Art. 16
https://knowledgeconnection.mainehealth.org/jmmc/vol1/iss1/16
DOI: 10.46804/2641-2225.1017
Atrial	fibrillation	(AF)	is	the	most	prevalent	and	frequently	
encountered	heart	arrhythmia	in	adults,	especially	within	the	
emergency	department	(ED).
With	frequent	ED	encounters	of	atrial	fibrillation,	medical	
costs,	hospital	visits	and	duration	of	procedures	are	high.
Studies	have	assessed	rate	control	with	chemical	
cardioversion	but	unfortunately,	successful	conversion	using	
medications	takes	hours	of	monitoring	each	patient	within	
the	ED	with	a	lower	success	rate	overall. Negative	
assumptions	about	complications	from	electrical	
cardioversion	impede	use	at	hospitals	everywhere.
However,	when	used	electrical	cardioversion	has	the	highest	
overall	success	rate	for	patients	presenting	with	atrial	
fibrillation.	Utilizing	electrical	cardioversion	as	a	primary	
treatment	method	for	atrial	fibrillation	will	lead	to	faster	
patient	turnarounds	within	the	emergency	department.	
Electrical	Cardioversion	of	Emergency	Department	Patients	with	Atrial	Fibrillation
Victoria	Vargas; Tania	Strout,	PhD,	RN,	MS;	Andrew	Perron,	MD
Emergency	Medicine	Department,	Maine	Medical	Center,	Portland,	ME
RESULTS
This	is	a	retrospective	review	of	electrical	cardioversion	cases	
performed	in	the	emergency	department	over	the	last	6
years.	By	describing	electrical	cardioversion	as	a	
management	option	in	preference	to	other	treatments	for	
atrial	fibrillation,	we	will	be	able	to	identify	factors	that	may	
predict	success	for	electrical	cardioversion	as	a	primary	
management	option.	Most	patients	ultimately	require	
electrical	cardioversion	despite	attempts	at	conversion	with	
medication.	The	average	visit	duration	for	cases	of	electrical	
cardioversion	was	206.67	minutes,	whereas	chemical	
cardioversion	requires	hours	of	observation	within	the	ED	to	
prove	success	in	converting	to	NSR.	Of	these	patients	
requiring	electrical	cardioversion,	13.5%	returned	to	the	ED	
for	atrial	fibrillation	or	related	event	within	30	days.
https://www.hrsonline.org/Patient-Resources/Treatment/Cardioversion
Table	1:	Percentage	of	patients	experiencing	complications	after	
electrical	cardioversion	procedures	within	the	emergency	department	
(n	=	680)
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METHODS
Maine	Medical	Center,	New	Hampshire-INBRE,	Dartmouth	
College	ISURF	Program
CONCLUSIONS
Emergency	Department	patients	presenting	with	atrial	
fibrillation	will	experience	shorter,	less	frequent	visits	when	
electrical	cardioversion	is	utilized	as	a	primary	management	
option	for	atrial	fibrillation.
HYPOTHESISABSTRACT
INTRODUCTION
• The	average	visit	duration	for	patients	requiring	chemical	
cardioversion	was	331.8	minutes,	verses	the	average	
duration	for	those	only	undergoing	electrical	cardioversion	
was	206.67	minutes.
• Only	13.5%	of	patients	returned	to	the	ED	within	30	days	
for	atrial	fibrillation	or	related	event	after	undergoing	
electrical	cardioversion.
Figure	3:	Average	ED	visit	duration	for	those	with	attempted	chemical	
cardioversion	verses	those	utilizing	only	electrical	cardioversion
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Figure	1:	Electrical	cardioversion	paddle	placement	on	patient	with	atrial	
fibrillation
Figure	2:	Sinus	rhythm	displayed	on	an	EKG	during	1)	atrial	fibrillation,	2)	
during	cardioversion	shock,	and	3)	during	return	to	normal	sinus	rhythm
1 2 3
RESULTS
Complication Percentage	of	patients
HR	<	50	bpm 3.4	%
Ventricular Tachycardia 1.8	%
Systolic	BP	<	90	mmHg 9.2	%
O2 saturation	<	90% 4.0 %
Intubation/Bagged 0.7	%
Figure	4:	Number	of	ED	patients	returning	to	the	ED	within	30	days	for	
atrial	fibrillation	or	related	event	(n	=	680)
n =	37 n =	612
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Characterization of exosomes secreted from human thermogenic adipocytes
Zainab Miguel, Chad Doucette, Aaron Brown
Maine Medical Center Research Institute, Scarborough, Maine,  Southern Maine Community College, South Portland, Maine 
Abstract
Accumulation of excess fat in white adipose tissue (WAT) is associated with an increase
in risk for type 2 diabetes (T2D). Unlike WAT, activation of brown adipose tissue (BAT)
burns calories by releasing energy stored in fats to generate heat. This process, termed
thermogenesis, correlates positively with a reduced risk for T2D. In addition to its fat
burning potential, secreted factors derived from activated BAT may enter the circulation
and reduce diabetic symptoms such as insulin resistance in other tissues. The
mechanisms by which these secreted factors act on distant tissues may in part be due to
their transport inside extracellular vesicles, known as exosomes. Exosomes carry a
diverse array of signaling molecules, including microRNAs, proteins and lipids that are
transported and released into recipient cells and tissues, potentially through direct
homing via specific cell surface receptors. The goal of this project was to determine if
brown adipocytes grown in cell culture secrete exosomes that contain microRNAs that
may harbor anti-diabetic properties. We found that miRNA-32, a microRNA previously
shown to activate brown adipocytes in a cell autonomous manner, can be packaged into
exosomes and secreted. These results suggest a hypothesis whereby BAT may export
exosomes containing miRNA-32 that activate other adipocytes and increase energy
expenditure, thereby reducing fat accumulation. Overall, administration of brown
adipocyte-derived exosomes to patients may be therapeutically beneficial for controlling
T2D if they can be harvested in sufficient quantities from cultured cells.
Hypothesis
We hypothesize that activated human brown adipocytes grown in cell culture can be
used to isolate exosomes to determine microRNAs that may alter gene expression in an
anti-diabetic manner in distant tissues. The major goal of this project was to develop the
methods necessary to isolate exosomes and determine their microRNA content.
Summary
We have demonstrated that activated brown adipocytes grown in cell culture secrete
exosomes, similar to what occurs naturally after cold induction in vivo. These exosomes
express microRNAs known to be expressed in brown adipocytes, which may play a
broader role in communicating with other adipose tissue depots. Thus, cell cultures of
activated brown adipocytes may provide an easy method to determine novel microRNAs
that regulate metabolism in distant tissues. Future studies will be directed against
sequencing microRNAs from exosomes isolated from cell cultures of brown adipocytes
in our search for molecules that may regulate type 2 diabetes.
Background
During weight gain, periods of prolonged overeating result in fat storage in white
adipocytes, which can lead to inflammation, cellular stress, insulin resistance and
eventually T2D. Unlike the energy storage function of WAT, brown adipocytes become
metabolically activated in response to cold and burn calories by releasing energy stored
in fats to generate heat, thereby providing mammals with protection from hypothermia.
Therapeutic strategies are being sought to stimulate brown adipocytes to burn excess
calories and combat obesity.
(A) Factors contained within exosomes secreted by brown adipocytes may target and
promote anti-diabetic effects on tissues affected by type 2 diabetes, such as the liver
and white adipose tissue. (B) Exosomes carry a diverse array of signaling molecules,
including microRNAs, proteins and lipids that are transported to recipient cells and
tissues, potentially through direct homing via specific cell surface receptors. (C)
microRNAs carried by exosomes can alter gene expression in distant tissues by
binding to specific mRNA targets and silencing them.
Methods
1) Grow brown adipocytes in culture.
2) Isolate exosomes from conditioned medium.
3) Purify microRNA from isolated exosomes.
4) Make cDNA from exosomal microRNA.
5) Test expression of microRNAs previously shown to be present in exosomes 
secreted by brown adipocytes in vivo.
Results
Isolation of exosomes from brown adipocytes
Exosomes were isolated from conditioned medium (3 days conditioning) using the Total
Exosome Isolation Reagent purchased from ThermoFisher Scientific. Briefly 4 ml of
conditioned medium was spun by centrifugation at 3000xg to removed cell debris and
was then combined with 2ml of Total Exosome Isolation reagent and incubated
overnight at 4C. Exosomes were isolated by centrifugation at 10,000xg for 1 hour, and
the resulting exosome pellet was re-suspended in PBS. Flow cytometry was used to
determine the presence of exosomes after staining for exosome surface markers CD9
and CD81.
Amplification of microRNAs from exosomes
microRNAs were extracted from exosomes isolated from brown adipocytes using the
Qiagen miRNeasy Micro Kit. microRNAs were converted to cDNA using gene specific
reverse transcriptase primers for 3 exosomal microRNA markers previously shown to be
expressed by brown adipocytes, including miRNA-92a, miRNA-99b and U6 snRNA. U6
snRNA is a non-coding small nuclear RNA commonly used as internal control to
normalize microRNA expression in cells. cDNA was amplified by qPCR using TaqMan
probe based assays for these 3 targets. These data suggest that we were able to
successfully isolate microRNAs from the exosomes of brown adipocytes.
miRNA-32 is enriched in exosomes compared to brown adipocytes
miRNA-32 expression was previously shown to necessary for activation of brown
adipocytes (Cell Rep. 2017, 19(6):1229-1246). We found that this microRNA is enriched
in exosomes (>85 fold) compared to brown adipocytes they were derived from. This
suggests that miRNA-32 may be secreted by brown adipocytes and play a role in
cellular communication, including the possibility of inducing the formation of brown
adipocytes in white adipose tissue. This could then lead to an increase in energy
expenditure and loss of body fat.
Analysis of RNAs isolated from exosomes using the Agilent Bioanalyzer
RNA isolated from either brown adipocytes or their exosomes was analyzed with the
Agilent Bioanalyzer. Exosomes isolated from brown adipocyte exosomes showed a gel
band in the approximate range expected for miRNAs (25-200 base pairs)
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1. Isolate mitochondria to run a SeaHorse assay to determine the dose of etomoxir that results in off 
target effects on the electron transport chain.
2. Determine the exact doses of etomoxir in combination with bortezomib and dexamethasone that are 
most effective in multiple myeloma cell lines.
3. Seed myeloma cells in direct, or indirect, co-culture with bone marrow adipocytes to investigate 
whether etomoxir has a greater negative effect on cell viability in a high lipid environment. 
4. Create a CPT1 knockdown model using lipofectamine and siRNA to see the effect of complete inhibition 
of fatty acid oxidation without the risk of off-target effects. 
5. Treat multiple myeloma cells with a combination of etomoxir and orlistat (fatty acid synthesis inhibitor) 
to try to reduce cell viability and to determine the role of lipids in myeloma cells. 
6. Create a drug combination therapy including etomoxir, orlistat, and anti-myeloma drugs. 
The Role of Lipid Metabolism in Multiple Myeloma
1. In Vitro Measurement of Cell Viability using Bioluminescent Imaging for MM Cells 
Treated with Etomoxir
MM1S bioluminescence 
read at 24 (A) and 72 (B) 
hours after various 
doses of etomoxir were 
added.  MM1S cells 
were seeded at a cell 
density of 40,000 
cells/well. OPM2 
bioluminescence read 
at 24 (C) and 72 (D) 
hours after various 
doses of etomoxir were 
added. MM1R 
bioluminescence read 
at 24 (E) and 72 (F) 
hours after various 
doses of etomoxir were 
added. 
*, p< 0.05; 
****, p< 0.0001 
FUTURE DIRECTIONS
Cell Culture: MM1S (gfp+/luc+), MM1R (gfp+/luc+), and OPM2 (mcherry/luc+) were seeded at various densities into 
clear and white 96 well plates.
Drug administration: Etomoxir (CPT1 inhibitor), Bortezomib (proteasome inhibitor), and Dexamethasone 
(corticosteroid that reduces inflammation) were added at various doses 24 hours after the cells were seeded. 
Bortezomib and dexamethasone are common pharmacological anti-myeloma treatments. 
Cell Number: Bioluminescent imaging (BLI) was used to quantify cell viability. Luciferin (10 µL) was added to each 
well and incubated for 15 minutes before reading with Glomax® Microplate Reader. BLI was read after 24, 48, 72, 
and 96 hours after the drugs were administered to the cells. 
1. We have seen a decrease in cell viability in our in vitro models with the MM1S, MM1R, and OPM2 
multiple myeloma cell lines when treated with etomoxir only.
2. Our preliminary data showing that etomoxir decreased cell viability, suggests that multiple myeloma 
may utilize fatty acid metabolism as a source of energy. 
3. Combination treatments of etomoxir with other anti-myeloma drugs, such as bortezomib and 
dexamethasone showed a significant decrease in cell viability when compared to the control in MM1S 
and MM1R cell lines.
4. While we are seeing a trend in a reduction of cell viability with the use of etomoxir in all cell lines, more 
research is required to confirm this data and refute any claims of off target effects.
•Multiple Myeloma (MM) is the second most common type of hematological cancer, formed from a series of 
oncogenetic mutations to the plasma cells of the bone marrow (1). 
•Initially patients respond well to chemotherapeutic treatment, but almost all eventually develop resistance to these 
treatments and experience relapse. 
•Myeloma thrives in the unique and complex  bone marrow microenvironment. Also, within the bone marrow are bone 
marrow adipocytes (BMA) that form bone marrow adipose tissue and account for 50-70% of the total bone marrow 
volume. It is believed that BMAT provides a source of energy that aids in multiple myeloma cell metastasis (2). 
•Fatty acid oxidation is the process by which cells convert long chain fatty acids into NADH, FADH2, and ATP in the 
mitochondria.  
•CPT1 is a transport enzyme in the outer mitochondrial membrane that transports long chain fatty acids into the inner 
mitochondrial space. It is the first, yet rate limiting enzyme of the carnitine system and subsequently of fatty acid 
oxidation (3).
•Etomoxir (Eto) is an pharmacological irreversible inhibitor of CPT1, effectively inhibiting fatty acid oxidation. 
•In other cancers, such as breast and prostate cancer, inhibiting fatty acid oxidation with the use of etomoxir has been 
proven to reduce cancer cell viability and proliferation. 
•Recently etomoxir has been shown to have off target effects by inhibiting complex one of the electron transport chain 
at high dosages (4).
INTRODUCTION
•In addition to a potential energy source, BMAT has been shown 
to increase MM’s resistance to chemotherapeutic treatments (5). 
•We are examining the effect of etomoxir on different MM cell 
lines and if it increases MM sensitivity to chemotherapeutic drugs. 
Objective and Aims: An in vitro investigation at the effects 
of inhibiting CPT1 on MM cells and to design a drug 
combination treatment that effectively reduces MM cell 
viability.
Hypothesis: Inhibiting fatty acid oxidation in multiple 
myeloma cell lines will reduce cell viability and increase 
their sensitivity to other chemotherapeutic drugs. 
Cell viability of (A) OPM2 and (B) MM1R cells treated with etomoxir (eto) at 0 µM, 5 µM or 12.5 µM, in addition to various 
doses of bortezomib (bort), specifically 0 nM,  0.25 nM, 1 nM, or 5 nM. Bioluminescence was used to measure tumor cell 
number and was read 72 hours after the drugs were administered. OPM2 cells were seeded at 20,000 cells/well in 96-
well plates. *, p<0.05; **, p<0.01.
2. In vitro Combination Treatment of Etomoxir and Bortezomib
3. In vitro Combination Treatment of Etomoxir and Dexamethasone Co-Cultured with 
MSCs 
MM1S cells were directly co-cultured with mouse 
mesenchymal stem cells (mMSCs) for 24 hours 
before etomoxir (5µM) and dexamethasone 
(0.5µM) were administered . The mMSCs were 
seeded at a cell density of 7500 cells/well. The 
MM1S cells were seeded at a cell density of 5000 
cells/well. Statistical analysis was done using one 
way ANOVA test. *, p<0.05; ****p< 0.0001.
A
B
OPM2: Etomoxir + Bortezomib
MM1R: Etomoxir + Bortezomib
Bioluminescence read 24 hours after 500 µM etomoxir was added to the 
cells. MM1S cultured at a cell density of 40,000 cells/well. 
****, p< 0.0001 
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E F
MM1S 24 hour
OPM2 24 hour
MM1R 24 hour
MM1S 72 hour
OPM2 72 hour
MM1R 72 hour
Eto 12.5µM
Figure 1 : Melone et al. Cell Death & Disease 2018. The carnitine system processes 
long-chain fatty acids across the mitochondrial membrane, forming acylcarnitine. 
Acylcarnitine then enters the mitochondrial matrix via carnitine-acylcarnitine
translocase (CACT) to undergo β-oxidation. Once in the form of Acetyl CoA, the 
fatty acid  enters the Krebs cycle to produce ATP. (6)
Eto 5µMEto 0 µM
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